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Summary 
Multi-omic characterisation of Barrett’s oesophagus reveals a molecular continuum in 
the progression to oesophageal adenocarcinoma 
Annalise Catherine Katz-Summercorn 
 
Barrett’s oesophagus (BE) is the main risk factor for the development of oesophageal 
adenocarcinoma (OAC) yet only 0.4%/year of non-dysplastic (ND) BE cases progress to 
cancer (Bhat et al., 2011). 
In this thesis I present the first comprehensive, multi-omics study comparing indolent, non-
progressors with those who progressed to a range of dysplasia grades. 
BE is highly heterogeneous with regards to mutational load, copy-number aberrations 
(CNAs) and structural variants (SVs). Mutational signatures are laid down early and persist 
regardless of progression status. Hence, Cosmic signature 17 (T:A>G:C in a CTT context), 
the hallmark of OAC, is visible in indolent, ND samples. TP53 mutation, GATA6 
amplification, ERBB2 amplification, APC mutation and whole genome doubling are 
confined to cases that have progressed with TP53 being by far the most prevalent. In contrast 
CDKN2A alteration occurs early in around 50% of indolent cases. SV analysis reveals a 
dominance of translocations from the early ND grade. 
Spatial analysis of multiple samples from across BE segments shows that the total mutation 
burden, total CNAs and total numbers of SVs to be surprisingly constant. However, clonality 
analysis highlights the complexity of BE, with some cases arising from a clear ancestral 
clone while others having minimal sharing of variants and showing heterogeneity in terms 
of driver events. 
Transcriptomic analysis reveals a clear but gradual differential gene expression between ND 
and dysplastic biopsies. We demonstrate a loss of the intestinal metaplasia phenotype with 
progression and downregulation of the HNF4A pathway, a transcription factor with roles in 
intestinal development. In progression there is an upregulation of genes in the ERK/MAPK 
pathway.  
In summary, BE is a heterogeneous disease that shows a continuum of abnormalities in the 
progression towards cancer. We hypothesise that it is the accumulation of events that tip the 
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balance to progression, rather than a stepwise model through the phenotypic dysplasia 
grades. Selected features could help to differentiate indolent from high risk disease and 
further work is being performed to identify scoring systems and biomarkers to apply in the 
clinical setting. 
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1. Introduction 
 
 Oesophageal adenocarcinoma epidemiology, presentation and 
management 
Oesophageal adenocarcinoma (OAC) is a malignancy arising from glandular epithelium 
usually occurring in the lower third of the oesophagus in proximity to the gastro-oesophageal 
junction. Although worldwide it is less common than its counterpart, squamous cell 
carcinoma (SCC), over the last 4 decades its incidence has been climbing, with more than a 
6-fold increase, and it has surpassed the incidence of SCC in a number of Western countries 
(Coleman et al., 2018). In the UK, approximately 9000 cases of oesophageal cancer are 
diagnosed each year, of which 55% are adenocarcinomas (Cancer Research UK). It is 
thought to develop from Barrett’s oesophagus (BE), a well-described, pre-malignant lesion 
which extends proximally from the gastro-oesophageal junction. 
Clinically, OAC most commonly presents with a progressive difficulty in swallowing, first 
to solids and later to liquids, persistent heartburn, weight loss, anorexia and fatigue. In 2016, 
of all OAC diagnoses in the UK, 65.2% were via referral from a GP but 13.7% presented via 
an emergency admission to hospital (Varagunam et al., 2017). Presenting via an emergency 
admission has a very poor prognosis. However, the outcome is not much better in the former 
scenario because once the tumour is symptomatic there is a high probability of spread to 
lymph nodes. Overall, approximately 60% of patients have advanced, palliative disease at 
presentation. (Varagunam et al., 2017). This failure to diagnose oesophageal cancer in its 
earlier stages results in an overall 5-year survival of only 20% in Western countries 
(Coleman et al., 2018). In contrast, only 0.5% of diagnoses are made during endoscopic 
surveillance for BE (Varagunam et al., 2017). Meaning that not only is it generally diagnosed 
at an advanced stage, but also that we are not very good at finding the ‘at risk’ population. 
OAC is diagnosed by the endoscopic appearance of the oesophagus coupled with 
histopathological analysis of biopsies. Further radiological investigations including CT and 
PET are then performed to determine the local invasion (T stage), lymph node involvement 
(N stage) and distant spread (M stage) of the disease (Figure 1, taken from (Thrumurthy et 
al., 2019). These are combined to give an overall staging of the tumour according to the 
Union for International Cancer Control-American Joint Committee on Cancer (UICC-
Introduction  
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AJCC) TNM staging 8th edition (Amin et al., 2017) (Table 1). This staging is a guide to the 
likely 5-year survival. If the cancer can be diagnosed early at stage T1 or Tis (in situ 
carcinoma), the 5-year survival is >80% (Coleman et al., 2018). 
  
Clinical stage T N M Management 5 year-survival 
0 Tis N0 M0 Endoscopic >90% 
I T1a, T1b N0 M0 Endoscopic/ surgical 80.5% 
II A T1 N1 M0 Surgical with neoadjuvant CRT 45.1% 
I B T2 N0 M0 Surgical with neoadjuvant CRT - 
III T2 N1 M0 Surgical with neoadjuvant CRT 17.6% 
 
T3, T4a N0, N1 M0 Surgical with neoadjuvant CRT - 
IV A T1-T4a N2 M0 Surgical with neoadjuvant CRT 2.1% 
 
T4b N0-2 M0 Palliative chemotherapy 
 
 
Any T N3 M0 Palliative chemotherapy 
 
IV B Any T Any N M1 Palliative chemotherapy - 
 
Figure 1 Definition of TNM staging of oesophageal adenocarcinoma 
T (tumour) stages is-4 refer to the depth of invasion of the tumour through the wall of the oesophagus.  Tis (in 
situ) has not invaded through the basement membrane of the epithelium. T1a (intramucosal) is confined to the 
mucosa, and T1b (submucosal) to the submucosa. T2: invasion through the submucosa; T3: full thickness 
invasion; T4: invasion into adjacent structures. N (nodal) stage is defined by the number of local lymph nodes 
involved. Referenced from Thrumurthy et al., BMJ 2019. 
Table 1 TNM staging, management and survival of oesophageal adenocarcinoma 
Clinical staging of oesophageal adenocarcinoma according to the pathological extent of the tumour through 
the wall of the oesophagus (T), the involvement of lymph nodes (N) and the presence of distant metastases 
(M). CRT = chemoradiotherapy. 5-year survival per stage taken from Coleman et al., Gastro, 2018.  
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The tumour stage will also determine whether the disease can be managed with curative 
intent or not. Endoscopic therapy has advanced significantly in the past 10 years, where 
previously oesophagectomy was the only effective treatment for early neoplastic lesions. 
Early tumours confined to the mucosa can be resected endoscopically by endoscopic 
resection of the mucosa (EMR) or submucosa (ESD) as the risk of lymph node (LN) 
involvement is small. The risk of LN involvement for T1b tumours has been shown to 
depend on the depth of the invasion into the submucosa (sm1 = limited to the superficial 
submucosa 6%; sm3 = invading >500um 58%) (Gockel et al., 2011). ESD +/- adjuvant 
therapy is now recommended for early T1b tumours (Othman et al., 2019) as ESD was 
shown to offer the same 5 year survival as surgery (Gong et al., 2017). ESD of sm2 and 3 
tumours are generally reserved for those unable to cope with the morbidity associated with 
an oesophagectomy. More advanced tumours with local nodal involvement are resected 
surgically with the local LN stations with neoadjuvant chemoradiotherapy. However, if the 
tumour has invaded adjacent structures, or in the presence of distant nodal disease or 
metastases, surgical resection is not possible and palliative chemotherapy is used. But 5-year 
survival for this stage IV disease is low at 2.1% (Coleman et al., 2018). If OAC could 
routinely be detected at Stages 0 or 1, survival would improve dramatically to >80%. 
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 Barrett’s oesophagus epidemiology, surveillance and 
management 
BE  is considered to be the main risk factor for the development of OAC and is thought to 
have a prevalence of 1-2% in the general population (Ronkainen et al., 2005; Zagari et al., 
2008). However, it has been estimated from screening studies that most cases go 
undiagnosed. Studies have found 10-15% of people with GORD are found to have BE on 
endoscopy, although risk is affected by the severity and duration of the symptoms 
(Lieberman et al., 1997; Westhoff et al., 2005). The main other risk factors are being male, 
obesity, age >50 and white race (Edelstein et al., 2009). Currently, the British Society of 
Gastroenterology does not recommend unselected population screening, but endoscopy can 
be considered in patients with chronic reflux and the above risk factors (Fitzgerald et al., 
2014). 
BE is a metaplastic condition in which there is a change from the normal squamous epithelial 
lining of the oesophagus to a columnar epithelium. It is thought to develop in a step-wise 
process, with increased risk of further progression at each stage: from a non-dysplastic (ND) 
glandular epithelium, to low grade dysplasia (LGD; risk of progression 11.6%/year (Phoa et 
al., 2014)), high grade dysplasia (HGD; 19%/year (Wani et al., 2009)), and then intramucosal 
carcinoma (IMC; adenocarcinoma confined to the mucosa) (Figure 2). 
  
  
Figure 2 Grades of Barrett’s oesophagus and rates of progression 
Haematoxylin and eosin-stained sections. BE = Barrett’s oesophagus. Rates of progression taken from Bhat et 
al. 2011, Phoa et al., 2014 and Shaheen et al., 2009. Image magnifications detailed. 
10x 10x20x20x
Non-dysplastic BE Low-grade dysplasia High grade dysplasia Intramucosal carcinoma
Progression rate/year
0.4%
11.6%
19-25%
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However, only 0.4%/year of NDBE will progress (Bhat et al., 2011; Desai et al., 2012) and 
it is not understood what drives this progression. Therefore, currently, all patients with BE 
are monitored endoscopically every 2-5 years. The Seattle Protocol recommends that 
quadrantic biopsies be taken every 2cm along the length of the segment to look for the 
presence of dysplasia or IMC. The need for such regular sampling of the BE segment is 
because dysplastic lesions are often flat and cannot be distinguished from the surrounding 
BE under white light endoscopy. Although the biopsies are taken systematically, there is the 
potential to miss focal areas of disease (sampling bias). Biopsies are assessed 
histopathologically for the presence of dysplasia. p53 immunostaining may be used as an 
adjunct to aid diagnosis and now features in the British and European guidelines (Bas 
Weusten et al., 2017; Fitzgerald et al., 2014) but is not yet recommended in the US (Shaheen 
et al., 2016). The evidence for dysplasia and p53 as biomarkers will be discussed further 
later in the chapter. 
Lesions with HGD or IMC are managed endoscopically. They can be resected by EMR or 
ESD and/or the area ablated by one of several methods including radiofrequency ablation 
(RFA), argon plasma coagulation (APC), photodynamic therapy (PDT) and cryotherapy. 
Randomised clinical trial data shows that treatment significantly reduces the cancer risk in 
patients with BE dysplasia: 2.4% vs 19.0% progression from HGD in the RFA group vs 
sham (at 12 months) (P=0.04) (Shaheen et al., 2009) and 1.5% vs 8.8% progression from 
LGD in RFA group vs surveillance (median follow-up 36 months) (Phoa et al., 2014). These 
studies have led to a change in practice so that intervention is routine for confirmed LGD 
(Fitzgerald, 2015; Fitzgerald et al., 2014; NICE, 2014). 
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 The genomics of oesophageal adenocarcinoma and Barrett’s 
oesophagus 
1.3.1 Oesophageal adenocarcinoma is highly mutated, rearranged and driven 
by copy number aberrations 
In order to understand the progression of BE, it is important to first consider the end stage 
of the progression, OAC. Over the last 10 years, with the technological advances of genomic 
sequencing, there have been huge international efforts to understand the molecular changes 
which confer a proliferative advantage to a cell and, therefore, drive tumourigenesis. The 
International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) 
spearheaded this with the genomic and exomic sequencing comparisons of large numbers of 
tumours. This led to many insights into the disease, showing that in OAC, somatic point 
mutations seem to be only a small part of the full picture and copy number aberrations 
(CNAs) and structural variants (SVs) are key features of the disease. However, this 
sequencing, whilst identifying new low frequency alterations in new oncogenic drivers, it 
has not identified any occurring at high frequencies. Instead it has highlighted the inter and 
intra-tumoural variation of OAC. 
OAC is a highly mutated, heterogeneous disease, with a median of 6.4 mutations/Mb (single 
nucleotide variants (SNVs) and indels) (Frankell et al., 2019). This is possibly due to the 
mutagenic environment of acid and bile that the lower oesophagus is subjected to in gastro-
oesophageal reflux disease. However, the majority of these mutations are synonymous, with 
a mean rate of only 151.4 non-synonymous somatic variants per genome. Disappointingly, 
the only gene found in these studies to be highly recurrently affected by point mutation is 
TP53 in 72% of cases (Frankell et al., 2019); already known to be the case from previous 
candidate gene studies from more than 20 years ago (Moore et al., 1994; Neshat et al., 1994; 
Prevo et al., 1999; Schneider et al., 1996). OAC is also dominated by aneuploidy and CNAs, 
which has long been known from single nucleotide polymorphism (SNP) array studies 
(Bandla et al., 2012; Frankel et al., 2014; Paulson et al., 2009) and more recently from WGS 
data e.g. (Secrier et al., 2016). Integration of these analyses with expression data has 
facilitated the identification of genes likely to be drivers due to alterations in expression by 
amplification or deletion. For example, when both point mutation and deletion were 
considered, CDKN2A was altered in 28% of tumours. Known oncogenes KRAS, MYC and 
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ERBB2 were amplified each in approximately 20% of cases (Frankell et al., 2019). Overall, 
76 driver genes have been discovered in OAC, with a median of five events in driver genes 
per cancer. Only 1% of cancers had no driver events identified but it is likely that we are still 
missing some of the lowest frequency events, especially in genes driven by CNA. 
Whole genome duplication (WGD), the acquisition of a complete second set of 
chromosomes within a cell, is a common phenomenon in cancer, thought to be due to errors 
in a number of mechanisms during mitosis e.g. cytokinesis failure. It has been shown to be 
more frequent in tumours with higher proliferation rates and has been associated with TP53 
mutation: a normally-functioning p53 prevents a WGD cell from entering the cell cycle and 
proliferating (Bielski et al., 2018). Chronologically, TP53 mutation occurs prior to WGD 
and this has been shown to be the case in 97.3% of patients across cancer types (Bielski et 
al., 2018). WGD has been observed in 50-62.5% of OAC (Secrier et al., 2016; Stachler et 
al., 2015). 
OAC has also been shown to be dominated by large scale structural rearrangements 
(structural variants, SVs) with a median of 263 SVs per tumour (Nones et al., 2014; Secrier 
et al., 2016; TCGA et al., 2017). These large-scale rearrangements can accumulate slowly 
over time, due to mitotic segregation errors, or rapidly by catastrophic evolutionary events 
of ‘chromothripsis’ (chromosome shattering). Chromothripsis has been exhibited in 30% of 
tumours (Nones et al., 2014). 
In addition to these signatures, 31% of OAC tumours exhibit a phenomenon called 
‘kataegis’, characterised by localised hypermutation dominated by C>T and C>G mutations. 
The exact importance of these events is unclear (Nones et al., 2014). 
1.3.2 Mutational Signatures in oesophageal adenocarcinoma 
Somatic mutations seen in individual tumours can be categorised into different combinations 
to further understand the biological processes and the exogenous and endogenous exposures 
generating the mutations. Rather than observing the specific genes which are altered by the 
mutations, the genome-wide shifts in base substitutions are analysed. There are 6 classes of 
single base substitution (SBS): C>A, C>G, C>T, T>A, T>C, T>G and these are considered 
in the context of their flanking 3’ and 5’ bases within the trinucleotide. This results in 96 
permutations of which the proportions of each within the genome are classified into 
signatures. 20 distinct signatures were initially described (Alexandrov et al., 2013) and this 
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has recently increased to 67 (https://cancer.sanger.ac.uk/cosmic/signatures/SBS/). In an 
analysis of WGS data on 129 chemo-naïve cases of OAC, six signatures were prominent 
(Figure 3). 
 
SBS17 is dominated by T>G substitutions in a CTT context. It was originally thought to be 
linked with acid reflux, however potential new causative factors are now being considered 
including reactive oxygen species (Pich et al., 2019). It is also seen following exposure to 
exogenous 5-fluorouracil (Christensen et al., 2019). It is considered the hallmark signature 
in OAC and has a variant of the signature with a higher frequency of T>C substitutions 
termed SBS17B. SBS3 is caused by defects in the BRCA homologous recombination 
pathway resulting in a complex set of mutations. SBS1 is the ageing signature, characterised 
by C>G mutations in a *CG context. SBS2 is dominated by C>T mutations in a TCA/TCT 
context from APOBEC-driven hypermutation. Finally, SBS18-like signature, previously 
described in breast and stomach cancers is a C>A/T substitution in a GCA/TCT context. In 
the analysis they considered the dominant contribution of these 6 signatures per case and 
identified three subgroups which suggested differing aetiology and differences in genomic 
stability. The three groups are: the DNA damage repair (DDR) impaired group (18%) which 
is dominated by the BRCA signature and has a high degree of genomic instability; the  
mutagenic subgroup (53%) which is dominated by S17 and has a significantly higher 
mutation rate than the other groups; and the C>A/T dominant subgroup (29%) which is 
predominantly the age and SBS18-like signatures and has the lowest rate of genomic 
 
Figure 3 Six mutational signatures identified in oesophageal adenocarcinoma 
Single base substitution (SBS) signatures described by Alexandrov et al., 2013 and shown to be prominent in 
oesophageal adenocarcinoma (OAC) (Secrier et al., 2016). ROS = reactive oxygen species. Percentages in 
OAC taken from TCGA data via COSMIC (https://cancer.sanger.ac.uk/cosmic/signatures/). 
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instability (Secrier et al., 2016). These subgroups have led to new hypotheses for therapy: 
e.g. mutagenic tumours, with a higher mutational burden and neoantigen load, may be more 
responsive to immunotherapy; and DNA damage repair (DDR)-impaired tumours may 
respond to treatment with PARP (poly ADP ribose polymerase) inhibitors. 
In summary, whilst OAC is highly mutated and heterogenous between patients, it seems to 
be dominated by copy number alterations in genes which drive progression of the disease. 
Large cohorts have been needed to identify these altered genes because of the low 
frequencies of recurrent alterations. Whole genome doubling and larger structural 
rearrangements are also seen. Algorithms can be used to predict the timing of events, but we 
do not know when these key alterations occur in the evolution of the disease. Studying 
Barrett’s oesophagus allows the possibility to investigate when these alterations occur pre-
progression. 
1.3.3 Barrett’s oesophagus is highly mutated and affected by copy number 
changes 
The molecular changes which drive the progression of non-dysplastic Barrett’s oesophagus 
(NDBE) to cancer remain incompletely understood despite the last 30 years of research.  
The genomic instability of BE was first demonstrated in the late 1980s using flow cytometry. 
Aneuploidy or an increased 4N fraction were associated with dysplastic and adenocarcinoma 
biopsies (Reid et al., 1987). These findings at baseline endoscopy also predicted progression 
(Reid et al., 1992, 2000). As technology improved, the importance of the accumulation of 
focal chromosomal aberrations during the metaplasia-dysplasia-carcinoma sequence was 
further shown using comparative genomic hybridisation, candidate region analysis and low-
density SNP arrays (Paulson et al., 2009; Riegman et al., 2001). But apart from the consistent 
early deletion of 9p21 and the late loss of heterozygosity of TP53, other results were highly 
heterogeneous, as seen in the cancer. 
Later, whole-genome, high-density SNP array studies were able to focus in on these changes 
at a higher resolution. One study considered the different stages of progression showing that 
in ND, LGD, HGD and OAC, the mean percentages of SNPs with allele loss increased: 
0.1%, 1.8%, 6.6% and 17.2% respectively (Gu et al., 2010). There were many recurrent small 
regions of loss in the later stages, disrupting single genes, predominantly at fragile sites, in 
addition to the expected losses of the loci containing TP53 and CDKN2A. 17p (containing 
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TP53) was lost in 5.3% of LGD, 25.0% HGD and 47.6% of OAC. 9p21 (the locus for 
CDKN2A) was lost in 68.4% of LGD, but only 5% of ND. However, both earlier and more 
recent studies have shown CDKN2A to be more frequently lost or mutated at the ND stage 
and not predictive of progression to OAC (Galipeau et al., 2007; Reid et al., 2001; Weaver 
et al., 2014). 
SNP arrays have also been used to compare the accumulation of CNAs over time in patients 
who go on to progress to cancer, versus those that do not. Genomes of non-progressors show 
very little genomic diversity and stable genomes over time. Conversely, in the progressors 
the genomes evolve significantly as they approach the cancer time point, with increased copy 
number variation, predominantly in the preceding 48 months prior to cancer diagnosis (Li et 
al., 2014). 
Most recently, the focus has been on WGS and whole exome sequencing studies (WES). 
Whilst efforts have mostly concentrated on the cancer, two studies sequenced the BE lying 
adjacent to OAC. They found this BE to also be highly mutated and heterogeneous, like 
OAC. The mutation rates in these cases of BE adjacent to cancer were, surprisingly, higher 
than that of many other invasive cancers: 1.3-6.76 mutations/Mb (Ross-Innes et al., 2015a; 
Stachler et al., 2015). The cohorts in these studies were small (n = 23-25) and the pathology 
of the BE samples predominantly ND. Of these, dysplastic BE appeared to have a higher 
mutation rate than the ND on WES, but this was not demonstrable at lower depth 50X WGS. 
In contrast, the ND cases had very few copy number changes compared to the cancer, with 
predominantly diploid genomes (median % of the genome with CN 2 = 99.7%; cancer: 
37.6%). Both studies found BE to be polyclonal, with surprisingly little overlap between the 
OAC and the adjacent BE (13/23 samples had <20% overlap of SNVs in one study). By 
sequencing multiple samples from individual patients, Ross-Innes et al were able to identify 
6 distinct clones present in one patient. On considering the BE clonally related to the cancer, 
Stachler et al. demonstrated that TP53 inactivation appeared to be an early event, followed 
by whole genome duplication (WGD) and subsequent further genomic instability. In their 
analysis, 62.5% of cases demonstrated this phenomenon. This concept of genome doubling 
could explain why some patients with BE progress rapidly to cancer. 
Despite this above work, important questions remain regarding the BE adjacent to cancer. 
For example, what is the local effect of the cancer on the surrounding area and whether this 
adjacent BE is representative of the pre-progression stages. Furthermore, given that the 
majority of the clones seen in the BE are unrelated to the adjacent tumour, this may be BE 
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that never had the capacity to progress. In order to answer these questions, the pre-malignant 
stages of the disease need to be considered. An earlier study used a next-generation 
sequencing 26-gene panel, based on the mutations observed in OAC WGS data. They 
compared the frequency of SNVs in specific genes in BE from patients who had never 
progressed to dysplasia (median follow-up >8 years) with biopsies from patients with HGD 
(Weaver et al., 2014). In the ND cohort (n=40), 53% had a mutation within the biopsy, and 
91% of the HGD cases (n=43) were mutated. It was surprising that a number of genes 
observed in HGD cases were mutated at low frequency in never-dysplastic BE, including 
ARID1A, SMARC4A and CDKN2A. Only TP53 mutation distinguished between the two 
stages (2.5% NDBE, 72% HGD), highlighting its potential use as a stage-specific biomarker, 
confirming previous studies. 
Since then, larger genomic panels have been used to compare the ND samples from patients 
who went on to progress and those that did not, introducing some uncertainty as to when 
TP53 mutations occur (Del Portillo et al., 2015; Stachler et al., 2015). A study using a 243-
gene panel found TP53 mutations in the biopsies at a time-point prior to progression to 
HGD/OAC (46%), but only in 5% of the non-progressors. However, the non-progressor 
group included patients with LGD and many cases were re-reviewed and downgraded to 
NDBE, which raises the question as to whether cases with TP53 mutations were downgraded 
appropriately. There was also no germ line comparison for mutation calling and TP53 
mutations were further manually curated. They did not observe significant differences in 
copy number profile or ploidy between the pre-progressors and the non-progressors ND 
samples either from the ploidy or in the more detailed analysis of CNAs. This finding was 
out of keeping with prior literature (Li et al., 2014). 
Overall, there have not been any large WGS studies of BE cohorts considering the stages of 
progression. One of the problems with panels is that the choices of genes on them are based 
our knowledge of cancer and de novo discoveries cannot be performed. They also do not 
permit the analysis of structural rearrangements and whole genome CNAs. Without being 
able to look at these we are missing key features for understanding how these events 
interplay in the progression of this heterogenous disease. 
1.3.4 Clonal diversity in Barrett’s oesophagus 
Another important consideration in the evolution of BE, that is becoming increasingly 
recognised, is how the clonal diversity of a segment relates to the risk of progression to 
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cancer. This was first shown in BE more than 10 years ago, when the Reid group adapted 
measures from ecology and evolution to quantify clonal diversity with the Shannon diversity 
index. The hypothesis was that the larger the number, and the more genetically different the 
clones within the BE segment were, the higher the potential for that segment to progress. 
Multiple biopsies per patient were assessed by flow cytometry, fluorescent in situ 
hybridisation (FISH) and TP53 and CDKN2A sequencing. The number of clones, Shannon 
index and genetic divergence, based on loss of heterozygosity (LOH), were strongly 
predictive of increased progression to OAC (Maley et al., 2006). The number of clones alone 
was a slightly better predictor of progression than the Shannon diversity and, given the ease 
of measuring the number of clones in a neoplasm, it has been suggested as a more useful 
measure. Interestingly, there were no significant differences in the Shannon diversity 
between tissues with and without 17q (TP53) or 9q (CDKN2A/p16) LOH, nor was it 
proportional to time since loss of TP53.  
FISH can also discriminate genetic diversity at a single-cell resolution and has been used on 
brush cytology specimens from BE patients. In a study comparing the baseline samples from 
progressors and non-progressors, genetic diversity could be seen on a single-cell basis, by 
scoring 50 cells based on four FISH probes. Across patients, loss of one p16 allele was 
observed in 51% (163) of patients, with complete loss in 5%. Overall, the level of clonal 
diversity at baseline in ND was indicative of progression risk and, importantly, did not 
change significantly over time (Martinez et al., 2016). The size of the biggest clone was not 
a prognostic marker: further supporting the findings that it is the number of clones, rather 
than clone size that is predictive of progression. Furthermore, p16 diversity was not a useful 
predictor of progression. 
The diversity seen at an individual crypt level in BE, using SNP arrays to measure CNAs, 
correlates with that seen at the biopsy level and does not provide additional information 
about genetic diversity (Martinez et al., 2018). However, proximity to the GOJ correlates 
with increased genetic diversity – which could explain the high incidence of tumours 
developing in the BE at the GOJ, rather than proximally. The idea that the progression risk 
of BE can already be determined at baseline has the potential to massively reduce the need 
for BE surveillance if it can be successfully translated into a diagnostic test. 
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 Expression analyses in Barrett’s oesophagus 
The focus of most RNA expression studies has been either looking for differentially 
expressed genes between OAC and NDBE or comparing NDBE to normal squamous 
oesophagus (NE). The main questions considered have been either about how the cancer 
develops or how BE develops in the squamous oesophagus.  
To date there has been one whole transcriptome study of BE and dysplasia with small 
numbers: 17 NE, 14 NDBE, 8 LGD and 12 OAC. The focus of the paper was on the 
expression differences between OAC and NDBE, however they did demonstrate the 
upregulation of 6 transcription factors, in LGD compared to NDBE, involved in cell 
proliferation, differentiation and transformation processes (Maag et al., 2017). Specifically, 
FOSB, NR4A1, EGR1, FOS, EGR3 and ATF3. An earlier study used gene expression from 
microarrays to find a 90-gene signature pattern which could differentiate HGD from NDBE 
(Varghese et al., 2015). 
However, whilst there remains controversy over the cell of origin of BE (Que et al., 2019) 
there is little evidence to support a transdifferentiation of squamous epithelium. With 
stronger evidence for an origin from either the submucosal glands or gastric cells 
(Nowicki-Osuch et al., 2019 (unpublished); Owen et al., 2018). Therefore, using NE as the 
tissue for comparison, as the above study did, is probably misleading. Phenotypically, BE 
with intestinal metaplasia shares many features with duodenum, and also the pyloric glands 
of the stomach. The epithelium is a combination of foveolar epithelium and goblet cells. In 
BE with IM, the brush border containing enterocytes is absent and the BE gland features a 
mucinous base compartment, which produces bicarbonate, and a specific repertoire of 
mucins. So, duodenum and gastric are better tissues for comparison when trying to 
consider the altered expression in BE. 
Expression data is key both for understanding the biological effects of genomic alterations 
but also for defining potential protein biomarkers from genes with increased expression. 
Whole transcriptome sequencing offers the further possibility of considering the non-coding 
RNAs in understanding the biology of progression. Overall, larger studies across the grades 
are needed. 
Protein studies can directly consider the changes occurring with progression. Prior to 
expression analyses, these mainly focussed on specific pathways in cell lines. Proteomics 
has been used to give an overall, unbiased approach in cell lines (Breton et al., 2008) and 
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human tissue but with a focus on the differences between the BE and the OAC, rather than 
the stages of progression (Elsner et al., 2012; O’Neill et al., 2017; Peng et al., 2008; Streitz 
et al., 2005; Zhao et al., 2007). The low throughput of proteomics has, so far, limited its use 
for detecting upregulated proteins in such a heterogenous disease. 
 Epigenetic alterations in Barrett’s oesophagus 
Modification of gene expression by aberrant DNA methylation plays a fundamental role in 
cancer development. It is another mechanism by which the expression of tumour suppressor 
genes and oncogenes is altered and compliments the effects of SNVs and CNAs seen at a 
genomic level. Methylation of cytosine residues, by DNA methyltransferases, occurs at CpG 
sites: where the cytosine is linked to a guanine residue by a phosphate. Areas of the genome 
with a high density of CpG sites are termed CpG islands and the hypermethylation of these 
areas and promotor regions results in transcriptional silencing and decreased expression of 
genes. Conversely, hypomethylation causes overexpression. 
Methylation-induced inactivation of CDKN2A is one of the commonest changes observed in 
BE metaplasia and it was the first gene found to be affected by methylation in BE in early 
gene-specific work (Wong et al., 1997). Methylation of its promoter region is seen in 15% 
of BE tissue, yet it is unmethylated in normal tissue (Hamilton et al., 2006). It seems to occur 
early in the process of progression and it is thought that the clonal expansion of p16-/- cells 
may form an environment conducive to the development of other genetic events, leading to 
OAC (Maley et al., 2004). There has been a lot of work to combine gene-specific methylation 
into panels in order to predict disease progression. For example, a 4-gene panel of 
SLC22A18, PIGR, GJA12 and RIN2 distinguished between NDBE and HGD/OAC with a 
97% specificity and 94% sensitivity in a retrospective cohort (Alvi et al., 2013). 
It has only been recently that the technology has developed to allow for an unbiased analysis 
across the whole epigenome, rather than focussing in on a limited number of CpG islands 
(27K arrays) and the differentially-methylated sites (Agarwal et al., 2012; Kaz et al., 2011; 
Xu et al., 2013). Using 450K arrays, OAC and BE have been shown to cluster together, with 
distinct separation from normal oesophagus (NE), suggesting that aberrant methylation is an 
early event in the stepwise progression of BE to OAC. However, as with the transcriptomics, 
this clustering could just represent the phenotypic differences between the glandular 
BE/OAC and squamous oesophagus. Stomach and duodenum are needed as comparisons to 
confirm if the methylation changes are really early events. 
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Hypermethylation is seen mainly within the CpG-rich promoters, with the regions outside 
being hypomethylated (shelf/gene-poor regions and the body of genes) (Krause et al., 2016). 
However, cohorts of BE to date have been small, with the focus predominantly on cancer. A 
study of 12 non-progressor BE and 12 progressor BE revealed global trends towards 
hypomethylation in the progressor group (Dilworth et al., 2019) although, oddly, they did 
not find a difference in CNAs between the two groups: a finding out of keeping with other 
studies. In a study of 125 OAC and 19 BE (11 taken at the cancer time-point), OAC/BE 
clustered into two distinct groups: a ‘gastric-like’ group and a ‘CpG island methylator 
phenotype (CIMP)-like’ group: a term first coined in colon adenocarcinoma. The 
methylation profile of the ‘gastric-like’ group was similar to that of gastric mucosa whereas 
the CIMP-like group were characterised by hypermethylation in the CpG islands. 
Interestingly, the top quantile of most hypermethylated tumours conferred a poor survival 
compared to all other tumours in the analysis. Methylation data was integrated with 
transcriptomics to show that 57% of testable sites correlated with gene expression changes 
(Krause et al., 2016). Epigenetic changes identified have the potential to be useful 
biomarkers in predicting disease stage and progression, especially if combined into 
integrated panels by using genomic features. 
 Integrated analyses 
It is becoming clear from work in other cancers e.g. lung and oesophageal squamous cell 
carcinoma (Farshidfar et al., 2017; TCGA, 2012) that the real power of these sequencing 
methods comes when the analyses are integrated. For example, expression data can highlight 
the downstream effect of a mutation or copy number change, and methylation can explain 
expression changes where no mutation is seen. For OAC, the integration of WES with SNP-
array profiling, DNA methylation profiling and mRNA/microRNA sequencing (TCGA et 
al., 2017) showed that CDKN2A, which is mutated in 15% of tumours (Secrier et al., 2016), 
was inactivated in 76% of OACs in total when mutation, deletion and epigenetic silencing 
were considered. And combining genomic with transcriptomic data has significantly 
increased the identification of driver events in OAC (Frankell et al., 2019). To date, however, 
analyses of this kind have mostly focussed on cancer, with only a few focussing on pre-
malignant lesions: colorectal adenomas, hepatocellular adenomas and pre-invasive lung 
cancer (Druliner et al., 2018; Nault et al., 2017; Qu et al., 2016; Teixeira et al., 2019). This 
type of analysis could be particularly useful in a disease as heterogeneous as BE. 
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 Clinical challenges and application to screening and 
surveillance 
Ultimately, the reason the evolution of BE needs to be understood better is so that we can 
improve management and early detection of the disease. There are a number of clinical 
challenges in the current management of BE. 
1.7.1 Diagnosing dysplasia 
Firstly, the histopathological diagnosis of dysplasia is the current gold standard for risk of 
progression of BE to OAC, but it is not perfect. Despite significant, quality evidence to 
support its use (Phoa et al., 2014; Shaheen et al., 2009) it does not excel as a biomarker 
because its diagnosis is so subjective, with inter-observer variability, and there is a 
propensity for overdiagnosis. The Sharma group found a kappa coefficient of 0.11 (95% CI 
0.004-0.15; none to slight agreement) between 3 pathologists for diagnosing LGD, clearly 
showing just how difficult it can be (Vennalaganti et al., 2017). A Dutch group demonstrated 
the likelihood of overdiagnosis by taking 293 LGD biopsies, diagnosed by a pathologist in 
the clinical setting, and subjecting them to review by an expert panel of pathologists. A high 
percentage, 73%, of the biopsies were downgraded to ND or indefinite for dysplasia. Of 
those which were confirmed to be LGD, there was a 9.1% per patient-year risk of 
progression. But this fell to only 0.6% and 0.9% per patient-year for the downgraded NDBE 
and indefinite biopsies respectively (Duits et al., 2015), clearly showing that dysplasia is an 
excellent predictor of risk, but only if correctly diagnosed. 
The only clinically recognised adjunct to dysplasia diagnosis is p53 immunohistochemistry 
and it has been widely studied as a biomarker. Protein accumulation can occur when TP53 
mutation in one of the alleles results in an increased half-life of the protein by stabilizing it 
and preventing degradation. This accumulation of p53 has been shown to precede 
development of HGD/OAC by several years (Davelaar et al., 2015), an important 
characteristic for a potential biomarker. Sikkema et al. found p53 over-expression to result 
in a five-fold increased risk of progression to HGD or OAC, independent of the presence of 
LGD (95% CI 2-14.5, p=0.004) (Sikkema et al., 2009), and other studies have shown to 
predict progression from LGD to HGD/OAC, with a 63.6-100% sensitivity and 68-93% 
specificity (Davelaar et al., 2015; Kaye et al., 2009; Murray et al., 2006; Skacel et al., 2002; 
Weston et al., 2001; Younes et al., 1997). Since then, it has been realized that not all 
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mutations stabilize the protein: they may truncate it or result in non-expression, and so the 
absence of staining for p53 has been recognized to also have clinical utility. The key studies 
looking at p53 are summarised in Table 2 (Bird-Lieberman et al., 2012; Davelaar et al., 2015; 
Galipeau et al., 2007; Kastelein et al., 2013; Kaye et al., 2009; Reid et al., 2001; Sikkema et 
al., 2009; Skacel et al., 2002; Weston et al., 2001; Younes et al., 1997). 
Biomarker Reference EDRN stage Sample size Finding 
TP53 LOH 
using flow 
cytometry 
Reid et al., 
2001 
Phase 3/4: 
prospectively collected 
samples, retrospective 
analysis 
325 RR=16, p<0.001 
Galipeau et 
al., 2007 
Phase 3/4: 
prospectively collected 
samples, retrospective 
analysis 
243 RR=10.6 (95% CI 5.2-21.3, 
p<0.001) 
P53 positive 
on IHC 
Younes et 
al., 1997 
Phase 3 retrospective 5 
progressors, 
25 non-
progressors 
Correlates with progression 
from LGD to HGD/OAC 
p=0.0108. 100% sensitivity, 
93% specificity in predicting 
progression. 
Weston et 
al., 2001 
Phase 4 prospective 5 
progressors, 
43 non-
progressors 
Kaplan-Meier curves 
differed significantly 
betweenp53 positive and 
negative patients with 
progression from LGD. 
Skacel et 
al., 2002 
Phase 3 retrospective 8 
progressors, 
8 non-
progressors 
Correlates with progression 
from LGD to HGD/OAC 
p=0.017. 88% sensitivity, 
75% specificity in predicting 
progression.  
Kaye et al., 
2009 
Phase 3 retrospective 154 
progressors, 
32 non-
progressors 
80% sensitivity, 68% 
specificity in predicting 
progression. 
Sikkema et 
al., 2009 
Phase 4 prospective 27 
progressors, 
27 non-
progressors 
HR 6.5 (95% CI 2.5-17.1) 
Kastelein et 
al., 2013 
Phase 3/4 
prospectively collected 
samples, retrospective 
analysis 
49 
progressors, 
586 non-
progressors 
P53 over-expression: RR 
5.6, 95% CI 3.1 to 10.3. 
Loss of p53 expression: RR 
14.0, 95% CI 5.3 to 37.2 
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Bird-
Lieberman 
et al., 2012 
Phase 3/4 
prospectively collected 
samples, retrospective 
analysis 
Nested-case 
control. 
89 
progressors, 
291 non-
progressors 
Risk of OAC alone OR 1.95, 
95% CI 1.04-3.67. 
P53 was not found to predict 
HGD/OAC progression in 
multivariate analysis. 
Davelaar et 
al., 2015 
Phase 4 prospective 116 patients Progression to HGD/OAC 
17 (95% CI 3.2-96, p=0.001. 
Progression to HGD only: 
OR 30.8 95% CI 3.78-308, 
p=0.002. IHC showed 
increased sensitivity (81.8%) 
but decreased specificity 
(85%) for progression to 
HGD when combined with 
FISH LOH. 
Table 2 Studies of p53 as a biomarker in predicting progression 
LOH = loss of heterozygosity, IHC = immunohistochemistry, FISH = fluorescent in-situ hybridisation, CI = 
confidence interval, RR = relative risk, HR = hazard ratio, EDRN = Early Detection Research Network, LGD 
= low grade dysplasia, HGD = high grade dysplasia, OAC = oesophageal carcinoma. 
 
Other features of TP53, whilst not used clinically, also predict progression risk or likelihood 
of dysplasia. Loss of heterozygosity (LOH) for TP53 was first shown in 2001 to be 
associated with a 16-fold increased risk of progression to OAC from NDBE (Reid et al., 
2001). However, LOH detection requires multiple technical steps making it not easily 
applicable to routine clinical use. TP53 mutation, as described earlier in the chapter has 
strong potential as a biomarker given that it is stage-specific: 2.5% never-dysplastic BE 
(n=66); 72% BE with HGD (n=43) (p<0.0001) (Weaver et al., 2014). However, on its own 
is not sufficiently sensitive given that we have shown that it is only mutated in 72% of 
dysplastic samples. Combination of TP53 mutation into biomarker panels may overcome 
this. Overall, to date, many studies have attempted to combine biomarkers into panels for 
diagnosing dysplasia (Eluri et al., 2018; di Pietro et al., 2015) but many of them include 
diagnosis of dysplasia in their prediction of progression (Duits et al., 2019; Parasa et al., 
2018). None so far have been promising enough to be further developed for clinical use.  
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1.7.2 Prediction of progression and endoscopy for surveillance 
The other main challenges in management are around the need for long-term surveillance 
with endoscopy. We are not able to predict the 0.4%/year of patients with NDBE who will 
progress to OAC. This puts a huge burden on the NHS in following these patients for many 
years. Furthermore, with no routine screening of the population for BE, only 7% of patients 
with BE and OAC have had their BE diagnosed in advance (Bhat et al., 2015). In addition, 
endoscopy, whilst the only recommended method for surveillance, has a number of 
limitations. It is expensive, time-consuming and unpleasant for patients but, more 
importantly, biopsies can miss focal areas of dysplasia or cancer (sampling bias). 
One way of overcoming sampling bias is moving towards cytological brush sampling 
methods e.g. the CytospongeTM which can be used in the community (Ross-Innes et al., 
2015a). These sample cells from the whole lining of the oesophagus but the structure of 
tissue is, somewhat, lost making diagnosis difficult except by experts in Cytology. 
Immunohistochemistry (IHC) staining using Trefoil Factor 3 (TFF3)  (Ross-Innes et al., 
2015b) or MUC2 (Zhou et al., 2019a) can diagnose the presence of BE, but currently these 
patients then need an endoscopy to investigate for dysplasia and enter into surveillance. This 
would put strain on an already busy National Health Service. Ideally, another level of test is 
needed to diagnose the presence of dysplasia on cytology or also to risk stratify patients and 
determine who is likely to progress. 
P53 IHC and TP53 mutation have been tested on Cytosponge samples as part of a panel with 
glandular atypia, aurora kinase A IHC, age, BE length and waist-hip ratio. All the patients 
in the low risk group were ND. 87% of patients in the high risk group were dysplastic, but 
the moderate risk group formed a large, mixed group who would still require an endoscopy 
(Ross-Innes et al., 2017). This showed the potential of applying a panel to FFPE cytology 
specimens. A commercial driver gene mutation panel has also been applied to a small cohort 
of FFPE Cytosponge samples to diagnose dysplasia with a 71.4% sensitivity and 90.3% 
specificity (Katz-Summercorn et al., 2017). These studies either used a few known 
biomarkers or large non-specific gene panels, highlighting the clinical need for an improved 
understanding of the key events driving the progression of BE. 
To address this overall clinical need, we need to start off by better characterising the stages 
of BE, in order to better understand the heterogeneity of the disease and what drives the 
progression of BE to cancer. 
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Hypothesis and Aims 
 
It was on this background of evidence that I formed the hypothesis that performing an 
integrated analysis of multiple sequencing modalities on the stages of Barrett’s oesophagus 
(BE) would overcome the heterogeneity of the disease, and lead to new insights about the 
key biological processes driving the progression of non-dysplastic BE to cancer. I undertook 
the creation of a cohort of patients in order to address the following aims: 
1. Elucidate the key biological processes driving BE to progress to oesophageal 
adenocarcinoma (OAC) by performing an integrated analysis of genomic and 
transcriptomic sequencing of the individual grades of BE. 
2. Consider the heterogeneity and clonal evolution of BE segments and how this may 
influence progression. 
3. Identify how the biological findings may be integrated with clinical information in 
order to categorise patients into high or low risk of progression. 
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2. Methods 
 
 Cohort design 
All Barrett’s oesophagus (BE) patients were selected from our Biomarker and BEST2 
Research Databases (Cell Determinants Biomarker Study: REC no. 01/149, BEST2 study: 
REC no. 10/H0308/71, Case1 study: Commercial; Rec. no. 14/EE/0015) for whom snap-
frozen samples had been collected at endoscopy. This biopsy sampling at endoscopy 
included both the strategic sampling of the Seattle protocol (quadrantic biopsies every 2cm) 
and targeted biopsy of raised lesions/abnormal areas on narrow band and autofluorescence 
imaging. Biopsies were frozen in liquid nitrogen in the endoscopy room and then stored on 
dry ice for transfer. Histology reports of FFPE diagnostic biopsies were used to identify 
patients with the different grades of disease. Patients were excluded if they had progressed 
past the grade of interest, either before or at a later date. This was in order to be absolutely 
certain of the grade being sequenced and negate the risk of local effects from prior higher 
grades. Equally, samples with imminent future higher grade of progression were excluded 
because of the possibility that the higher grade was already present and missed at Barrett’s 
surveillance. Patients were also excluded if they had received previous ablative treatment of 
their BE. Biopsies representing the independent grades could not be adjacent to cancer. Non-
progressor patients with long follow-ups and long segments were selected where possible 
and pre-progressor samples were taken as far in advance of progression as available. In 
addition, cases of BE adjacent to cancer (Trio BE: cancer-BE-normal) were selected as a 
comparison (OCCAMS Rec. no. 10-H0305-1). These frozen samples were taken either from 
the oesophagectomy specimen or at the staging endoscopy. BE was sampled at the greatest 
distance possible from the tumour to avoid contamination (Table 3). 
All biopsies underwent a strict, uniform pathology review process. A section from each 
frozen biopsy was cut and stained with haematoxylin and eosin (H&E) and reviewed by a 
consultant pathologist to assess the composition of the biopsy. For the main, pre-cancer BE 
cohort, any potentially suitable biopsies were then reviewed independently by a further 2 
consultant pathologists. All pathologists were blinded to the grade of the patient. Sample 
grade was determined by an agreement of at least two pathologists. Samples with no 
agreement were reviewed by the 3 pathologists together to reach a consensus. Dysplastic 
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samples for sequencing had to have a pathological cellularity of dysplasia of >30% and were 
included even if the dysplasia was not all the highest grade the patient was known to have. 
Cellularity refers to the percentage of the tissue which is composed of dysplastic BE cells, 
with the rest composed of e.g. NDBE, stroma, squamous contamination and immune cells. 
A 30% minimal cellularity was used to try to ensure that 50X sequencing would cover the 
pathological mutations to an adequate depth but balanced against having enough samples in 
the cohort. Cellularity was assessed by the eye of the pathologist. Whilst it is known that this 
can lead to an overestimate in cellularity, the same method has previously proven successful 
in our lab for tumour sequencing (Secrier et al., 2016). NDBE biopsies had to contain 
intestinal metaplasia (IM). Samples with only gastric metaplasia were avoided because this 
phenotype of BE has an extremely low risk of progression and surveillance is not 
recommended for short-segment GM (Fitzgerald et al., 2014). For the Trio BE cohort, H&Es 
were reviewed independently by two pathologists and only dysplastic cases reviewed a third. 
Trio BE samples were excluded if there was any tumour contamination in the biopsy. Across 
the whole cohort, no squamous epithelium could be present in any sample however, samples 
with inflammation were not excluded. Duodenum was used as the germline reference as 
blood had generally not been collected. Where not available, blood was used if possible or 
normal squamous oesophagus (verified with H&E staining) in that order. 
 
Essential inclusion criteria Preferable inclusion 
criteria 
Exclusion criteria 
>= 30% cellularity for 
dysplasia in dysplastic 
samples, or IM in non-
progressor samples 
Long prior follow-up for 
non-progressors 
Previous thermal ablative 
therapy 
Consensus pathology review 
Snap frozen tissue 
Long overall follow-up Prior higher grade 
Matched germline available Good clinical annotation Future higher grade within 
1 year 
 >50% cellularity Squamous contamination 
  Tumour contamination 
  Absence of IM in non-
progressors (i.e. only 
gastric metaplasia) 
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  Adjacent to cancer for the 
pre-cancer cohort 
Table 3 Inclusion and exclusion criteria in cohort creation 
IM = intestinal metaplasia 
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It was found, on reviewing the H&Es of cases, that the frozen sample rarely captured the 
highest grade which the patient was known to have at that timepoint, highlighting the 
problem of sampling bias. For example, a patient who had a small focus of HGD on their 
FFPE diagnostic biopsy, but the research frozen biopsy at that level was taken in an 
alternative quadrant and did not capture this focus. As a result, it was decided to accept any 
grade of dysplasia in dysplastic cases, rather than just the highest grade. E.g. a patient has 
IMC but the biopsy is composed of 50% HGD. Further rational for this was the difficulty 
for pathologists in assessing the frozen tissue, with the relative loss of structure due to the 
freezing process. The most difficult group to make was the LGD group, as many could not 
be used as contained only IM. The pre-progressor group was equally difficult to create, as it 
required a patient to have been surveilled for a significant number of years prior to 
progressing and had research biopsies on those occasions. 
Multiple levels were later selected for six cases for the heterogeneity analysis. The same 
criteria as above were used for identifying these samples. 
In total, 1161 frozen biopsies from 315 patients were found, cut and reviewed for inclusion. 
See Figure 4 for a summary of the cohort creation and Figure 5 for patient examples. 
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Figure 4 Flow diagram of cohort creation 
GI = gastrointestinal, WGS = whole genome sequencing, BE = Barrett’s oesophagus, ND = non-dysplastic, 
ND-NP = non-dysplastic non-progressor, ND-PP = non-dysplastic pre-progressor, LGD = low grade dysplasia, 
HGD = high-grade dysplasia, IMC = intramucosal carcinoma, D2 = 2nd part duodenum, NE = normal 
oesophagus, GC = gastric cardia 
Insufficient DNA for WGS:
12 BE, 7 D2, 12 NE
6 BE failed sequencing
121 BE identified with >30% cellularity
of grade of interest 
2 mismatched
1 removed as no dysplasia on re-review
1161 frozen biopsies from 315 patients
H&E cut and reviewed by 1 of 3 GI Pathologists
Research databases searched manually to
identify patients fitting selection criteria
All potential biopsies reviewed independently
by the other 2 GI Pathologists 
DNA and RNA extracted for 243 biopsies:
121 BE and tissue germline (2 blood) 
WGS: 109 BE 50X and matched germlines 30X
103 pre-cancer BE
Pipelines: Strelka, Battenberg, Manta 
100 pre-cancer BE:
27 ND-NP, 12 ND-PP
15 LGD, 25 HGD, 21 IMC
 Addition of:
• 47 BE adjacent to cancer
• 15 additional biopsies from 6 patients
for multilevel analysis
RNA seq: 93 BE
(25 ND-NP, 10 ND-PP, 12 LGD, 25 HGD, 21 IMC)
 Addition of:
• 31 BE adjacent to cancer
• 80 normal tissues (18 D2, 38 NE, 24 GC)
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Figure 5 Cohort examples 
Endoscopy, histology and timing of biopsies for example patients in cohort. H&Es of frozen biopsies shown to 
highlight the increased difficulty in pathology review due to the snap-freezing preservation technique. 
Timelines of patient progression and sample sequenced given. EMR = endoscopic mucosal resection, RFA = 
radiofrequency ablation, ND = non-dysplastic, IMC = intramucosal carcinoma. C and M values describe the 
circumferential (C) and maximal length (M) of the Barrett’s oesophagus segment in cm. 
 
2005 2008 2011 2014 2017
TIME
years
70yo male
C0 M4
27 pack/yr history
60yo male
C2 M2
12 pack/yr history
2002
EMR
+
RFA
Stable NON-DYSPLASTIC
75yo male
C7 M8
20 pack/yr history EMR
RFA
Sequenced biopsy
Intestinal metaplasia
Low grade dysplasia
High grade dysplasia
Intramucosal carcinoma
Gastric metaplasia
Neosquamous
PRE-PROGRESSOR
HIGH GRADE DYSPLASIA
ND
COHORT
EXAMPLES
Endoscopy dates
IMCHIGH GRADELOW GRADE
Methods  
45 
 DNA/RNA extraction 
Whole frozen biopsies were homogenised on the Precellys® and DNA and RNA were 
extracted using the AllPrep DNA/RNA Mini Kit (Cat No. 80204; Qiagen®, Germany), as 
per protocol and performing all additional optional steps to maximise yield. DNA was eluted 
in 100ul EB buffer and RNA in 30ul RNA-free water. RNA was initially quantified using 
the Nanodrop. DNA was quantified using the Qubit® Low Sensitivity assay on the Qubit® 
2.0 fluorometer (Invitrogen, Life Technologies, UK). 20ng/ul concentration of DNA was 
required for whole genome sequencing. For the pre-cancer cohort, DNA and RNA were 
extracted from 243 biopsies in total (121 BE and 122 germline) of which 31 had insufficient 
DNA for WGS (Figure 4). Blood was extracted as the germline reference for two cases using 
the QIAmp Blood Maxi kit (Cat No. 51192; Qiagen®, Germany). A further 62 biopsies and 
their matching normal tissue samples had DNA and RNA extracted for the multilevel and 
BE-adjacent to cancer analyses. A cohort of normal tissue biopsies (18 D2, 38 NE, 24 GC) 
had RNA extracted for comparison in the expression analysis. NE biopsies had an H&E cut 
prior to use to ensure they were only composed of squamous epithelium. 
 DNA library preparation and sequencing 
A total of 124 pre-cancer BE biopsies (matched BE-germline) and 47 BE adjacent to cancer 
(Trio BE) were sequenced from 153 patients, under Illumina contracts. 100-bp paired-end 
sequencing was carried out to an average depth of 50x for BE 30x for matched normal. 
Library preparation for the further multilevel samples was performed in house using the 
TruSeq DNA PCR-Free kit (Illumina, CA) as per protocol with a 2ug input. These 15 
samples were run over 4 lanes of the NovaSeq 6000 sequencer (Illumina, CA) at the 
Cambridge Cancer Institute, Cambridge, UK, to a depth of 50x. Sequencing output from 
these batches were compared to previous sequencing to ensure that they were equivalent. 
 Whole genome sequencing analysis 
2.4.1 Pipelines for variant callers 
The FastQC package was used to assess the quality-score distribution of the sequencing 
reads and perform trimming if necessary. Read sequences were mapped to the human 
reference genome (GRCh37) using Burrows–Wheeler alignment (BWA-mem) 0.7.17 (Li 
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and Durbin, 2009). Duplicates were marked and discarded using Picard 2.9.5 
(http://broadinstitute.github.io/picard/). Six BE samples failed WGS due to insufficient 
coverage. No samples had evidence of microsatellite instability using MSIsensor (Niu et 
al., 2014). 
Somatic mutations and Indels were called using Strelka 2.0.15 (Saunders et al., 2012) with 
additional filters (Table 4). 
Overall, 98% of the known genome was sequenced to at least 10x coverage and 60% to a 
50x coverage. The whole cohort had at least 85% aligned bases within a read with a Phred 
quality of 20 or higher. 
 
Filter Cut-off 
Variant Allele Count < 4 
Variant Allele Count Control > 1 
Distance to Alignment End Median < 10.0 
Distance to Alignment End MAD  < 3.0 
Variant Map Qual Median < 40.0 
Map Qual Diff Median v < -5.0 or > 5.0 
Low Map Qual > 0.1 
Variant Base Qual Median  < 30.0 
Variant Strand Bias < 0.02 
        and Strand Bias > 0.02 
SNV Cluster 50 > 2 
SNV Cluster 100 > 4 
Repeat >= 12 
Table 4 Strelka filters 
 
Structural variants were identified using Manta 0.27.2 (Chen et al., 2016). Discordant reads 
and split reads were used to identify putative breakpoint junctions. These methods have been 
compared to other variant callers in the ICGC benchmarking exercise and have among the 
best sensitivity and specificity (Alioto et al., 2015). Single nucleotide polymorphisms were 
called using GATK HaplotypeCaller 3.2-2 (McKenna et al., 2010). Copy number was 
initially called using ASCAT 2.3 (Van Loo et al., 2010); however, it was recalled using 
Battenberg v2.3.2 (Nik-Zainal et al., 2012a) which was able to call subclonal copy number 
for the clonality analysis.  
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Using the ASCAT output, WGD was seen in 11% ND-NP (3/27), 0% ND-PP, 21% LGD 
(3/14), 39% HGD (10/26), 30% IMC (6/20) (Figure 6). We were surprised by this calling of 
WGD in NP cases but further investigation did not highlight any obvious reasons for this. 
They were all TP53 mutation negative and the cellularity estimates were not at either extreme 
(0.46, 0.51 and 0.23). 
In comparison, with the Battenberg output all ND cases were diploid. The LGD and IMC 
proportions with WGD did not change from ASCAT, but the proportion of HGD cases with 
WGD halved to 19%. 
Estimates of cellularity correlated well between ASCAT and Battenberg. However, a 
comparison of ploidy showed ASCAT to be possibly over-calling a number of samples 
(Figure 6). We looked at the raw ASCAT output for these cases and found that ASCAT had 
struggled to call these cases and the second alternative fit correlated better with Battenberg. 
Further comparisons between the two callers did not show any significant differences for 
calling clonal copy number so we decided to move over to this caller completely for the 
analysis. 
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Figure 6 Whole genome duplication: ASCAT versus Battenberg 
a. ASCAT ploidy estimates against loss of heterozygosity (LOH) proportion of genome. Samples in the upper 
cluster are considered to have undergone WGD. b. ASCAT proportions of samples with WGD per grade. c. 
Correlation between ASCAT and Battenberg cellularity output. d. Correlation between ASCAT and Battenberg 
ploidy estimates. e. Battenberg ploidy estimates against loss of heterozygosity proportion of genome. f. 
Battenberg proportions of samples with WGD per grade. WGD = whole genome doubling, ND = non-dysplastic, 
NP = non-progressor, PP = pre-progressor, LGD = low grade dysplasia, HGD = high grade dysplasia, IMC = 
intramucosal carcinoma. 
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DPClust was then run to cluster mutations by cancer cell fraction (CCF), given the copy 
number profile from Battenberg. After removal of artefactual mutation clusters containing 
<1% of the total number of mutations for that sample, if a clonal cluster of mutations was 
found (within CCF boundaries =0.95-1.05), and this had the highest CCF, or the largest 
number of mutations, this sample was classed as 'passed'. Where these conditions were not 
fulfilled, the sample was marked as 'failed' and required a rerun with new purity (rho) and 
ploidy (psi) parameters. Rho was calculated using the cluster that was closest to falling 
within the clonal boundaries. The rho value of the current call, and calculation of psi 
following that, was as follows: 
rho_2 = rho_1*CCF of clonal cluster 
psi_2 = ((rho_1 * psi_1) + 2*(rho_2 - rho_1))/rho_2 
The copy number fitting steps of Battenberg and DPClust were then rerun to produce an 
updated call, and the test for 'passing' or 'failing' a profile was repeated. A large proportion 
(an additional ~20%) of samples which failed the first run typically now passed with these 
criteria. 
For the small number which had not passed by this point, a further rerun was 
performed using a reference segment that was likely to have been called incorrectly by 
Battenberg. This was identified manually, and a new solution proposed, defined as a major 
and minor allele copy number. This proposed new copy number solution, along with 
information from calculation of the BAF and logR from the subclones file for this segment, 
was used to calculate a further estimate for the purity (rho) and ploidy (psi_t) of the sample. 
The copy number fitting steps of Battenberg and DPClust were then rerun for a final a time 
to produce an updated call, and the test for 'passing' or 'failing' a profile was repeated, 
allowing for a further set of copy number profiles to be included into analysis. 
Whole genome duplication (WGD) was called using the PCAWG method (Dentro et al.) 
which plots the ploidy relative to the fraction of the genome with loss of heterozygosity 
(LOH). 
2.4.2 Mutational signatures 
A de novo discovery of mutational signatures was performed using the non-negative matrix 
factorisation methodology (NMF) described by Alexandrov et al (Alexandrov et al., 2013) 
using the python version of SigProfiler (https://www.mathworks.com/matlabcentral/ 
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fileexchange/38724-sigprofiler). For identifying optimal de novo signatures, we ran NMF 
for 2-10 ranks for 1000 iterations. This process identified 3 optimal signatures which, when 
decomposed, mapped to 8 known signatures. The de novo signatures were compared to the 
50 known published COSMIC signatures (https://cancer.sanger.ac.uk/cosmic/signatures/ 
SBS/). 
2.4.3 Structural variant signatures 
SV signatures were identified based on a framework as explained in Nik-Zainal et al., 2016. 
Briefly, SVs were classified into 38 categories based on the type and size of SV event, then 
were further classified into clustered and non-clustered. Events were considered to be 
clustered in a sample if a region of the genome (1Mb) was covered by >10 breakpoints. NMF 
was then applied on these events using Palimpsest (Letouzé et al., 2017), identifying 5 
optimal signatures. 
2.4.4 Chromothripsis  
We identified both low and high confidence chromothripsis event based on oscillating copy 
number events in regions with clustered breakpoints across all samples using ShatterSheek 
(Cortés-Ciriano et al., 2018). 
2.4.5 Kataegis 
Clustered mutations representing Kataegis-like events within small genomic loci (5kb) 
were identified across all samples using a package in R called ClusteredMutations 
(https://cran.rproject.org/web/packages/ClusteredMutations/index.html). 
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 RNA sequencing 
2.5.1 Library preparation 
RNA was quantified using the Qubit High Sensitivity RNA kit (Thermo Fisher) and checked 
for quality (RNA integrity number; RIN) on the Agilent 2100 Bioanalyzer® (Agilent 
Technologies, USA) using the RNA 6000 Nano kit. Samples with insufficient material, or 
an incalculable RIN were excluded. There was no other lower limit for RIN inclusion. 
Samples were randomised to 3 batches, ensuring an equal spread of RIN values across the 
batches. Libraries were prepared with an input of 150ng RNA using the TruSeq Stranded 
Total RNA High Sensitivity protocol with ribosomal depletion. Samples with less than the 
specified input, but with >100ng total were included and this was noted for the analysis. 
Libraries were validated using the Agilent 2100 Bioanalyzer with the DNA 1000 kit and 
KAPA quantification (KAPA Biosystems, Roche, Switzerland) and were pooled according 
to the Illumina protocol. Samples were run on the HiSeq 4000 instrument to generate 75bp 
paired-end reads. A mixture of normal expression controls was run on each plate: squamous 
oesophagus, gastric cardia, duodenum. Duodenum shares some features of intestinal 
appearance of BE and it is hypothesized that BE arises from gastric cells. Squamous 
oesophagus is a less useful comparison because it shares few features with the glandular 
epithelium of BE. 
2.5.2 Pipelines for RNA 
RNA sequencing data was trimmed for poor quality bases using Trim Galore 
(https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) and was then aligned 
using STAR (Dobin et al., 2013) using ENSEMBL gene annotation. Reads per gene were 
quantified using the summariseOverlaps function from the GenomicRanges package, which 
was also later used for computing Transcripts per million (TPM). Normalised expression 
data was corrected for batch effect using the ComBat function in the sva package (v3.20.0) 
(Johnson et al., 2007). Expression was calculated as log2(1+TPM). Principal component 
analysis was performed selecting the 1000 most variable protein-coding genes. DESeq2 
software (v1.18.1) (Love et al., 2014a) was used to compare the differential expression 
between the different groups using the raw counts. Genes were considered to be significant 
if there was a >3-fold change and p <0.05. Pathway analyses were performed using DAVID 
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6.8 (Huang et al., 2009b, 2009a), Ingenuity Pathway Analysis (IPA; Qiagen, Germany), 
StringDB (https://string-db.org) and Gene Set Enrichment Analysis. 
2.5.3 Copy number driver gene discovery 
GISTIC 2.0 (Mermel et al., 2011) was used to identify recurrently amplified and deleted 
regions from the raw copy number calls; a method that has been previously used in the lab 
(Frankell et al., 2019). Peaks were widened by 1 million base pairs up- and down-stream and 
all genes falling within these regions were considered. The expression (calculated as the 
log2(1+TPM) of each gene from the RNA seq data was compared for high vs. normal CN 
samples for each gene and mean expression levels compared using the Wilcoxon rank sum 
test. The Benjamini-Hochberg method was used to correct for multiple testing. 
2.5.4 Immune signatures and chromosomal instability 
Markers for both immune cell types and chromosomal instability were retrieved from 
publication. (Carter et al., 2006; Tamborero et al., 2018) and Gene Set Variation Analysis 
(GSVA) was used to assign enrichment scores to samples based on the expression of 
different markers in bulk RNA seq (Hänzelmann et al., 2013). 
 Heterogeneity/clonality methods 
DPClust v2.2.5 (Nik-Zainal et al., 2012a) was used to model clonal expansions by 
calculating the cancer cell fraction (CCF) of each mutations (as described above). Clusters 
containing fewer that 1% of the total number of mutations were excluded. Phylogenetic trees 
were constructed manually using this output. 
 Clinical modelling 
The rpart package in r was used with 16 features from genomic, expression and clinical data 
to grow a classification tree. 
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3. Results 1: The genomic landscape of Barrett’s 
oesophagus 
 
Aim 1: Elucidate the key biological processes driving Barrett’s oesophagus (BE) to progress 
to oesophageal adenocarcinoma (OAC) by performing an integrated analysis of genomic and 
transcriptomic sequencing of the individual grades of BE. 
• Perform a genomic characterisation of the grades of BE. 
• Compare non-dysplastic samples that do not progress to those prior to progressing to 
see if genomic alterations can be defined which predict that progression will occur. 
• Compare the genomic alterations in BE sampled from adjacent to cancer to pre-
cancer BE. 
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  Cohort selection and demographics 
In order to characterise the stages of Barrett’s oesophagus (BE) progression, samples were 
identified from patients with different grades of disease from non-dysplastic (ND) BE to 
intramucosal carcinoma. ND samples were split into two categories: samples from long-term 
ND patients who had never gone on to progress (denoted non-progressor, NP); and patients 
who had gone on in the future to progress to dysplasia (denoted pre-progressor, PP). 
Dysplastic samples were split into low grade (LGD), high grade (HGD) and intramucosal 
carcinoma (IMC). Strict criteria were applied for sample selection and these criteria, plus 
further details for cohort creation, are detailed in the Methods. All biopsies in the cohort 
were reviewed independently by three specialist BE pathologists. Biopsies were categorised 
both by the highest grade which the patient had reached on the date of the endoscopy and by 
the highest grade seen in the H&E of the sequenced biopsy. 
In total, 1161 frozen biopsies from 315 patients were identified, cut and reviewed in order 
to create the final pre-cancer cohort (Figure 7). All of these cases had germline samples 
available to determine somatic mutations from inherited polymorphisms. Blood had not been 
taken in the study, so we used duodenum, in preference to normal oesophagus. This is 
because it is far removed from the BE and not at risk of being genetically altered by a field 
effect. Previous studies in the literature have predominantly used BE adjacent to 
adenocarcinoma to elucidate the progression stages (Ross-Innes et al., 2015a; Stachler et al., 
2015). Therefore, as a comparison to our cross-sectional cohort of pre-cancerous disease 
stages, we also included samples from BE adjacent to cancer from 47 patients: so-called 
Barrett’s oesophagus Trios (BE, cancer, germline).  
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The final cohort was determined by which cases had successful generation of whole genome 
sequencing (WGS) data. Six samples failed QC at Illumina and were excluded. Two cases 
appeared hypermutated, but further investigation showed this to be due to a mismatch 
between the sample and the germline reference: one ND-NP with 231,692 mutations; and a 
ND-PP with 239,153 mutations. One pre-progressor sample was excluded from further 
analysis because, on pathology consensus review, the criteria for inclusion had not been met. 
It had been taken at a LGD time-point only two months prior to a further endoscopy which 
found HGD. The biopsy available for sequencing contained only IM, and so was not suitable 
for inclusion in the cohort. This resulted in a pre-cancer BE cohort of 100 patients (27 ND-
NP, 12 ND-PP, 15 LGD, 25 HGD and 21 IMC) plus 47 Trio BE (Table 5). The median total 
follow-up in the ND-NP was 138 months (range 45-251) in order to give confidence that 
they were long-term non-progressors. 
Male gender, increasing age, length of the BE segment and smoking are recognised risk 
factors for the development of BE (Coleman et al., 2014; Krishnamoorthi et al., 2018). 
However, there were no significant differences between the three groups for gender or age 
 
Figure 7 Cohort design 
Cohort design and annotation terminology 
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(complete data available for all patients); or length of BE between ND and dysplastic 
(complete data available for all pre-cancer cohort patients but not recorded for the Trios BE) 
(Table 5). There was a significant increase in smoking status (complete data for 80% of 
cohort) in the dysplastic group versus ND (ND 51.7%, dysplastic 83.0%; p value = 0.0047, 
Fisher’s Exact Test) but the increase in the Trio BE cases compared to ND was not 
significant (p value = 0.13). The use of a proton pump inhibitor (PPI) has also been found to 
lower the risk of progression (Krishnamoorthi et al., 2018).We saw a trend towards fewer 
Trio BE patients being on a PPI (ND 94.9%, dysplastic 96.7%, Trio BE  77.5%, p value = 
0.04 Fisher’s Exact Test; 97% complete data). There was no significant difference between 
BMI (89% complete data) or non-steroidal anti-inflammatory (NSAID; 77% complete data) 
use. The cohort was predominantly of white ethnicity. This may be reflective of the higher 
incidence of BE amongst Caucasians (Corley et al., 2009), but also the demographic of the 
East of England region in which this study took place. 
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Table 5 Clinical demographics of the final cohort 
P values calculated using Fisher’s Exact test for categorical variables and T-test for continuous variables. 
Statistical comparisons made between ND and dysplastic groups, and ND and Trio groups. BMI = Body mass 
index, PPI = proton pump inhibitor, NSAID = Non-steroidal anti-inflammatory drugs, BE = Barrett’s oesophagus, 
ND = non-dysplastic, NP = non-progressor, PP = pre-progressor, LGD = low grade dysplasia, HGD = high grade 
dysplasia, IMC = intramucosal carcinoma, OAC = oesophageal adenocarcinoma. % given exclude NA patients. 
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 Pre-cancer Barrett’s oesophagus cohort 
3.2.1 Mutational burden 
Next we considered the overall genomic features of the groups, starting with the mutation 
burden. BE biopsies were found to be highly mutated, as previously described (Ross-Innes 
et al., 2015a; Stachler et al., 2015).There was a median of 14,126 mutations (IQR 9,580-
20,914) across the coding and non-coding genome, with a median mutation burden of 4.5 
mut/Mb. None of the samples had microsatellite instability. All sequencing studies 
conducted on tissue samples can be affected by the cellularity of the sample i.e. the 
proportion of BE cells within the whole sample. Large proportions of normal tissue will 
lower the allele frequency of a mutation and may take it below the threshold for being called 
by Strelka. However, the mutation burden did not generally correlate with the cellularity of 
the biopsy calculated by the Battenberg algorithm (Figure 8a) One LGD sample 
(LP6008280-DNA_B04) had only 175 mutations. Battenberg had difficulty calling the 
cellularity of this sample and so the low mutation burden was likely false and due to a low 
cellularity of BE in the biopsy. It was excluded from further analysis (circled in red in Figure 
8a). 
The median mutation burden increased linearly with patient grade, but with wide ranges 
(Figure 8b). There was a significant difference in mutation burden when LGD, HGD and 
IMC were grouped together as dysplastic and compared with all ND cases (median ND 3.19 
mut/Mb; median dysplastic 5.62mut/Mb; p = 5.9x10-6, Wilcoxon Rank Sum test) (Figure 
8c). There was no evidence that the actual grade within the frozen biopsy correlated better 
with mutation burden than the highest grade of disease in the patient, suggesting that the 
overall clinical patient status was most informative (Figure 8b). This may be because there 
is a local effect within the segment where the dysplasia arises. However, it may also be 
because of the difficulty for pathologists in distinguishing between LGD and HGD in frozen 
biopsies because of the artefact caused by ice crystal formation and thawing. This was 
exemplified by 7 of the 14 biopsies which were from patients diagnosed with LGD from 
their surveillance FFPE biopsies, however the pathology review consensus of the frozen was 
of HGD. These biopsies were analysed using the diagnostic FFPE pathology grades for this 
reason. 
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Figure 8 Mutation burden across the grades 
a. Scatterplot showing the relationship between the cellularity called by the Battenberg algorithm and the total 
number of mutations per sample. The sample circled in red were excluded from subsequent analyses because 
of a low mutation count due to low cellularity. b. Mutation burden per grade of patient that biopsy taken from. 
Dots coloured by highest grade of Barrett’s oesophagus (BE) within the biopsy: which may be lower than the 
highest grade in the patient overall. c. Mutation burden in ND versus dysplastic BE. y axis log10 scale. ND = 
Non-dysplastic, NP = non-progressor, PP = pre-progressor, LGD = low grade dysplasia, HGD = high grade 
dysplasia, IMC = intramucosal carcinoma. P values calculated using Wilcoxon Rank Sum test. 
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Next, we determined the mutational signatures in the samples. Mutational signatures 
consider the proportions of each base substitution within the context of the immediately 5’ 
and 3’ bases. We applied the algorithms derived by Alexandrov et al (Alexandrov et al., 
2013) using SigProfiler (Alexandrov, 2019). A de novo discovery of mutational signatures 
using non-negative matrix factorisation extracted 9 signatures (Figure 9). SigProfiler 
automatically compares the de novo signatures to the known mutational signatures 
(https://cancer.sanger.ac.uk/cosmic/signatures/SBS/) in order to assign their likely 
aetiology, if known. The proportions of these signatures in each sample are shown in Figure 
10. No new signatures were discovered but this was not unexpected given the arguably small 
size of the cohort for a de novo discovery. 
All of the 9 signatures, except signature 9, are seen in OAC, particularly signatures 1 (ageing; 
C>G substitutions in a *CG context) and 5 (unknown aetiology; T>C in an AT* context). 
Signatures 17a (T>C in a CTT context) and b (T>G in a CTT context) are considered the 
hallmarks of OAC (Secrier et al., 2016). They are closely related signatures of unknown 
aetiology, although thought to be caused by reflux/reactive oxygen species (Pich et al., 2019; 
Tomkova et al., 2018). They are commonly found in the same samples and have previously 
been shown to correlate with mutational burden in OAC (Secrier et al., 2016) which was 
also the case in our pre-cancer cohort (Figure 11). The mutational signature profile has 
previously been shown to be unchanged between the cancer and its adjacent prevalent BE 
(Ross-Innes et al., 2015a) but it has not been known when it is set. Here we found that 
signature proportions did not change significantly across the pre-progression grades. 
Signatures 17a and b were present even in the ND samples i.e. from an early stage. Signature 
18, observed in 20% of OAC, was also present from the early ND stage. We also observed 
signature 1, associated with ageing, to negatively correlate with mutational burden. Although 
the total proportions of the signature (maximum 20% total proportion) was lower than those 
of signature 17. 
Signature 2 (APOBEC-driven hypermutation; (Nik-Zainal et al., 2012b)) was seen in 52% 
of the cohort and is in 39.5% of OAC. Signature 9, which is not seen in OAC, was present 
in 3 samples (3%). We did not observe representation of signature 3 (BRCA-related; (Nik-
Zainal et al., 2012b)) which is present in 7% of OAC (Alexandrov et al., 2018). 
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Figure 10 Mutational signatures in the cohort 
Number of mutations per case contributing to each signature and proportions of each signature per case. 
Grouped by grade and ordered within that from high to low mutation burden. SBS = single base substitution, 
ND = Non-dysplastic, NP = non-progressor, PP = pre-progressor, LGD = low grade dysplasia, HGD = high 
grade dysplasia, IMC = intramucosal carcinoma, ROS = reactive oxygen species, OAC = oesophageal 
adenocarcinoma. 
 
 
Figure 11 Correlation of mutational signatures 17 and 1 with mutation burden 
Proportion of signature 17 (A+B) or signature 1 in each sample plotted against mutation burden. Dots 
coloured by grade of patient. Dashed line is line of fit by linear regression. ND = non-dysplastic. 
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3.2.2 Copy number aberrations across the grades 
In view of the importance of copy number alterations in OAC, this was evaluated in the pre-
cancerous BE stages. The Battenberg algorithm (Nik-Zainal et al., 2012a) was used to call 
copy number, tumour purity and ploidy. Battenberg was chosen instead of ASCAT because 
it is able to estimate both clonal and subclonal events. A comparison of these two methods 
for our dataset is included in Methods. 
The mean ploidy of the ND was 2.00 (median 2.00, range 1.92-2.02) and the dysplastic mean 
2.29 but with a wider range up to 4.27 (median 1.99, range 1.67-4.27) highlighting the likely 
presence of duplicated genomes amongst the dysplastic cases. From the Battenberg output 
we were able to distinguish the types of CNAs that were occurring: amplifications, 
amplifications with loss of heterozygosity (LOH) of the minor allele, deletions, deletions 
with LOH of the minor allele and copy number neutral LOH. In this chapter, total % CNA 
refers to the addition of the proportions of these 5 types of gain and loss multiplied by 100. 
Figure 12a shows the proportions of each of these alterations within the samples. Copy 
number neutral LOH was the most frequent alteration observed, followed by deletion LOH. 
As seen with mutation burden, dysplastic cases had significantly more CNAs than ND cases 
(median ND 7.9%, dysplastic 11.4%, p value = 1.5x10-6, Wilcoxon Rank Sum test), with a 
wide variance between cases which increased with grade of dysplasia (Figure 12b). Of the 
five most extreme dysplastic outlier cases, circled in red in Figure 12c, four were mutant for 
TP53. There was one ND-PP with a higher % CNA than the other ND samples but this case 
was also not TP53 mutant. However, what was particularly noticeable in these five cases 
was the high number of structural variants (SV): median 292 total SV count, range 128-517). 
This will be discussed further in the next section.  
When we performed a sub-analysis by the grade of the patient there was a trend towards an 
increase in copy number (Figure 12c). However, there was no correlation within a sample 
between its total mutation burden (TMB) and CNA (Figure 12d), such that a high TMB was 
occurring in different samples to those with a high percentage CNA. We also considered 
whether the grade composition of the frozen biopsy, rather than the grade of the patient, was 
affecting the CNA levels seen but this did not appear to be the case. A LGD biopsy from a 
HGD patient had the highest CNA in the HGD patient group, as did a HGD biopsy in the 
IMC patient group (Figure 12c). 
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 Figure 12 Copy number aberrations across the grades 
a. Percentage and type of copy number aberration per sample ordered by grade. b. Copy number aberration 
in non-dysplastic versus dysplastic samples. c. Copy number aberration per grade of patient that biopsy 
taken from. Dots coloured by highest grade of BE within the biopsy. Dots circled in red are outliers 
discussed further in the text. d. Comparison of copy number and mutation burden per sample. ND = Non-
dysplastic, NP = non-progressor, PP = pre-progressor, LGD = low grade dysplasia, HGD = high grade 
dysplasia, IMC = intramucosal carcinoma. P value calculated using Wilcoxon Rank Sum test. 
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Given that whole genome duplication (WGD) is a common event in OAC we wanted to look 
at the proportions of samples with WGD and the timing of this occurrence. The PCAWG 
method (Dentro et al.) was used to determine if a sample had undergone WGD. The method 
plots the ploidy relative to the fraction of the genome with loss of heterozygosity (LOH). 
Using the Battenberg output, WGD was not observed in any of the ND-NP or ND-PP (Figure 
13). LGD and HGD had similar percentages 21% (3/14) and 19% (5/26) respectively. This 
increased to 30% in IMC (6/20) but the increase was not significant compared to HGD (p 
value = 0.52, Fisher’s Exact test). We analysed the cancers matching the BE Trio samples 
as a comparison and observed WGD in 75%. Other studies have observed 62.5% (Stachler 
et al., 2015) and 50% (Secrier et al., 2016) WGD in OAC, but used different methods for 
calculating it e.g. ploidy > 2.7. When we used this cruder cut-off, 59.6% of the tumours were 
whole genome duplicated. So, a similar percentage to the other studies. 
  
 
 
Figure 13 Whole genome duplication in the cohort 
Battenberg estimates of whole genome duplication (WGD). ND = Non-dysplastic, NP = non-progressor, PP 
= pre-progressor, LGD = low grade dysplasia, HGD = high grade dysplasia, IMC = intramucosal carcinoma. 
0.00
0.25
0.50
0.75
1.00
ND-NP ND-PP LGD HGD IMC
Patient grade
Pr
op
or
tio
n
No WGD
WGD
Results 1: The genomic landscape of Barrett’s oesophagus  
66 
We then used the WGD as a reference to determine the relative timing of other gains and 
losses. This analysis was performed by considering the variant allele frequencies of 
mutations in relation to the copy number in that region and the sample purity, to give the 
number of chromosomes with the mutation. From this, mutations were split into those that 
occurred before the chromosomal gain (as they are in two alleles) or afterwards (in only one 
allele). 
Figure 14 plots the timing of the CN gain relative to the mutational time. 100% indicates 
when all the mutations in a specific sample had occurred. Timing can only be relative, not 
real-time, given that mutation acquisition occurs at different rates in different patients. We 
found in our whole genome duplicated samples that there was a prolonged mutational period 
prior to the duplication. In most cases more than 80% of mutations had been acquired prior 
to the duplication; indicating that WGD is a late event. However, in the non-WGD samples 
the copy number gains were more evenly acquired over the duration of mutational time. 
WGD has previously been suggested to be an early event, with subsequent oncogene 
amplification and rapid progression to OAC (Stachler et al., 2015). However, they focussed 
on OAC and its adjacent BE. It is possible that we are capturing an alternative evolutionary 
pathway by studying samples prior to progression. 
  
 
Figure 14 Timing of whole genome duplication 
The y axis represents a timeline from the first mutation to the acquisition of 100% of mutations in an 
individual sample. The box plots mark the percentage of mutations present when each copy number (CN) 
gain in the sample took place. The red line is an arbitrary threshold at 80% which shows that most of the 
CN gains in whole genome duplicated (WGD) cases occurred after this threshold. Whereas samples with 
no WGD gained CN in a more evenly distributed manner, over the lifetime of mutation acquisition. 
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We next looked at the locations and sizes of these CNAs across the genome in order to 
understand if specific regions were recurrently affected. Figure 15 shows the amplifications 
and deletions per chromosome for each patient. Regions were binned according to the 
number of breakpoints in the region, across the whole cohort. The genomic landscape was 
dominated by deletions. The most commonly deleted loci were the fragile site in 
chromosome (chr) 3 containing FHIT and the locus of chr 9 containing CDKN2A. 
Hierarchical clustering divided the cohort into two main clusters; however, there was no 
clear distinction between ND and dysplastic samples. Earlier in the analysis we had seen a 
significant difference between ND and dysplastic cases when just considering the means of 
the total proportions of CNAs (Figure 12). But the ranges had been wide and a number of 
dysplastic samples had had low proportions of CNAs. In this regional analysis we did not 
see distinct genomic loci which cleanly split the grades. 
One main branch of the clustering dendrogram predominantly consisted of dysplastic 
samples. However, two distinct groups of dysplastic samples, with fewer CNAs, clustered 
with ND. Both these groups were lacking the large chr 9 deletion, which dominated the other 
dysplastic cases. One cluster did not have a deletion of the short arm of chr17 (containing 
TP53) but instead amplifications of parts of chr 8, 9, 17 and 18. The other cluster was 
dominated by both amplifications and deletions in chr 16-22. The samples in these clusters 
were a mix of LGD to IMC. Hence, the clustering by copy number was, to some extent, 
independent of the grade of dysplasia. Overall, from this analysis, the transition from ND to 
the extremes of dysplasia seems to be more of a continuum, with a gradual acquisition of 
copy number alterations; some of which are hotspots e.g. the fragile sites, and others private 
to the sample. 
We considered individually the 13 dysplastic outlier cases with fewer CNAs, clustering more 
with the ND samples in Figure 15 (marked as dysplastic outliers). Whilst they had fewer 
deletions, amplifications within chr 8, 9, and 18 were prevalent. These amplifications will 
be further considered later in the chapter with the driver analysis. Seven of the cases had 
clear alternative explanations for progression: 2 were whole genome duplicated, 4 were 
TP53 mutant and the others either had high mutation burdens or numbers of SVs despite 
little copy number change (Table 6). None exhibited chromothripsis. 
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3.2.3 Structural variation 
In order to call structural variants (SVs: translocations, inversions, large scale deletions and 
duplications) we used the Manta pipeline (Chen et al., 2016). When the total number of SVs 
in each sample was calculated we found that there was a larger and more significant 
difference between ND and dysplastic samples that out-weighed the variables considered so 
far: ND median 43 (IQR 35.0-60.5), dysplastic median 140.5 (IQR 78.5-256), Wilcoxon 
Rank test p value = 1.6x10-11 (Figure 16a). It was also observed that the ranges of SV count 
per sample was wider for the HGD (22-876) and IMC (38-1602) samples versus the ND-NP 
(9-85) and ND-PP (10-128) (Figure 16b). Of note, total numbers of SVs did not correlate 
with either CNAs or ploidy on a per-sample analysis (Figure 16c, d). 
When examining samples on a case by case basis, we observed that some dysplastic samples 
had a low copy number burden but highly rearranged genomes, notably dominated by 
translocations. The top three circos plots in Figure 17 show examples of this. The fourth case 
demonstrates a more representative level of rearrangement: a HGD patient with 70 SVs and 
11.1% total CNA (proportion of whole genome affected by gain or loss using same criteria 
as in section 3.2.2). The fifth is a ND-NP for comparison with only 9 SVs and no CNAs.  
Chromothripsis, chromosomal shattering due to mitotic segregation errors, is observed in 
30% of OAC (Secrier et al., 2016) but this complex phenomenon has not been looked at in 
the pre-cancer stages apart from in a very small cohort of five HGD cases among which 
chromothripsis was observed in one case (Newell et al., 2019). In our cohort, chromothripsis 
was observed in one ND-NP case, but then from HGD onwards: 1/27 (3.7%) ND-NP; 0/12 
(0%) ND-PP; 0/15 (0%) LGD; 4/26 (15.4%) HGD and 4/20 (20%) IMC. This confirms that 
these alterations are seen in the pre-malignant setting. 
  
Results 1: The genomic landscape of Barrett’s oesophagus  
71 
 
  
 
Figure 16 Structural variation across the grades 
a. Total number of structural variants (SVs) (translocations, inversions, tandem duplications and large-scale 
deletions) grouped by overall grade. b. Total number of SVs by patient subgrade. c. d. Correlation between 
number of SVs and copy number aberrations (CNA) and ploidy per sample, coloured by dysplasia status.  
ND = Non-dysplastic, NP = non-progressor, PP = pre-progressor, LGD = low grade dysplasia, HGD = high 
grade dysplasia, IMC = intramucosal carcinoma. P value calculated using Wilcoxon Rank Sum test. 
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Figure 17 Circos plots of individual cases 
Each outer circle represents the chromosomal ideogram. The inner wider circle displays the position and 
type of structural variant (red = deletion, blue = inversion, green = duplication). The middle circle tracks 
the translocation of one region to another part of the genome (grey). Grade of patient, mutation burden 
(SNV), percentage of copy number aberrations (CNA), ploidy and TP53 mutation status are listed above 
each plot. The second case shows patterns consistent with chromothripsis. ND = Non-dysplastic, NP = non-
progressor, HGD = high grade dysplasia, IMC = intramucosal carcinoma. 
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Given the wide variation in the burden of SVs that we observed, we ordered the samples by 
this metric and found a gradual continuum with progression of dysplasia grade, with no 
apparent point at which a step-change occurred (Figure 18). 
 
 
  
 
Figure 18 Samples ordered by burden of structural variants 
Structural variant (SV) count plotted for each sample in order of total SV number. a. Samples colour coded 
by their overall grade. b. Samples colour coded by the patient grade with biopsy grade detailed below. ND 
= Non-dysplastic, Dysp = dysplastic, NP = non-progressor, PP = pre-progressor, LGD = low grade 
dysplasia, HGD = high grade dysplasia, IMC = intramucosal carcinoma. 
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The signatures of rearrangements, described initially by Nik-Zainal et al., can be considered 
in order to understand the patterns of SVs dominating the samples and to complement the 
base substitution signatures (Nik-Zainal et al., 2016). SVs can be classified as inside or 
outside of clusters. Clustered SVs occur when multiple breakpoints occur close together in 
the same region. SVs can then be classified by their type and size. The same non-negative 
matrix factorisation methods that are used for base substitution signatures can then be 
applied. We extracted five dominant signatures from our samples (Figure 19a). 
Rearrangement signature 1 is characterised by un-clustered translocations and deletions. 
Signature 2 is mainly un-clustered tandem duplications 10kb-1Mb. The SVs in signature 3 
are clustered and dominated by very large (>1Mb) inversions, but also clustered deletions 
and tandem duplications. Signature 4 is comprised of un-clustered deletions and 5 is almost 
uniquely clustered translocations. 
Signature 5 (clustered translocations) was seen across all grades (Figure 19b). 
Proportionally, it was higher in the samples with fewer SVs. However, the total number of 
SVs per case attributed to signature 5 was quite consistent throughout the grades: median 
counts (IQR) ND-NP 23 (16-31); ND-PP 16 (5-23); LGD 35 (26-46), HGD 41 (21-55), IMC 
56 (22-82). Clustered translocations are likely to correspond to the fragile site regions of 
FHIT and WWOX, which we know are affected by CNAs in the ND stage. This suggests that 
these regions become focally affected by SVs early, with little further change with 
progression. Signature 2 (unclustered tandem duplications), in contrast, whilst also seen 
across the grades, is dominant in samples with low SV burdens. Signature 3 is dominated by 
samples with a high total number of SVs. Therefore, it appears that as samples become more 
rearranged, clustered deletions, tandem duplications and inversions are the predominant 
alterations that occur. Total numbers of these types of SVs may therefore be more useful 
than translocations, or an overall SV count, to classify the grade. There was no observable 
correlation between SV signature and TP53 mutation status (Figure 19b: samples with TP53 
mutation marked with asterisks). 
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Figure 19 Structural variant signatures 
a. The proportions and sizes of each structural variant (SV) type present in the signature. Split into clustered 
(left) and unclustered (right). Probability of rearrangement on y-axis. Rearrangement size on the x-axis. Del 
= deletion, tds = tandem duplication, inv = inversion, trans = translocation. b. The proportions of each SV 
signature contributing to our samples relative to total number of SVs. Samples grouped by grade and ordered 
by total number of SVs from high to low. Asterisks mark TP53 mutant samples. ND = Non-dysplastic, Dysp 
= dysplastic, NP = non-progressor, PP = pre-progressor, LGD = low grade dysplasia, HGD = high grade 
dysplasia, IMC = intramucosal carcinoma. 
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 Driver gene analysis in the progression of Barrett’s oesophagus 
In order to consider the specific genes that might be driving the progression of BE, a de novo 
analysis was performed to look for CN and SNV driver genes using GISTIC (Beroukhim et 
al., 2007), MutSigCV (Lawrence et al., 2013) and dNdScv (Martincorena et al., 2017). In 
addition to this, we considered the frequency of alterations in driver genes known to be 
altered in >10% OAC from our consortium (Frankell et al., 2019). 
3.3.1 Copy number driver genes 
For copy number drivers, we took the significantly amplified and deleted loci annotated by 
GISTIC and considered 1 million base pairs in each direction, in order to not miss any 
potential drivers in the flanking up and downstream regions. We then compared the 
expression of genes in wild type samples for a given gene versus those with a copy number 
change at that locus. Genes that were deleted in at least 5% of samples were included in our 
driver gene analysis. Eight of these genes were found to have a significantly lower 
expression between the deleted versus wild type samples (q value < 0.05). However, these 
eight genes all fell within the same GISTIC locus 9p21.3, containing CDKN2A (Figure 20, 
Figure 21). CDKN2A encodes p16INK4A which inhibits cyclin dependent kinases 4 and 6, 
thereby activating Rb protein and preventing G1-S phase cell cycle traversal. It is already 
known to be deleted early in BE and is a driver in OAC. C9orf53 encodes an anti-sense RNA 
to CDKN2A. It was felt that the other genes in the region were passengers. No other deleted 
regions resulted in a significant loss of expression.  
 
Figure 20 Genes with significantly reduced expression on 9p21.3 
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Figure 21 Expression of genes in significantly deleted regions 
Eight genes with a significant difference (q value <0.05, False Discovery Rate; Wilcoxon Rank Sum for p 
value) in expression between deleted and wild type cases, where at least 5% of cases have a deletion. Log 2 
expression plotted for each group. Comparison to expression in normal tissues. BE = Barrett’s oesophagus, 
TPM = Transcripts Per Kilobase Million. 
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In contrast, using the same parameters for the amplified regions 57 genes were significant. 
To narrow it down we applied more stringent filtering to remove those with very low 
expression in the mutant samples (log2 expression <1). This reduced the list to 43 genes 
within 3 GISTIC loci 17q21.2, 17q12 and 18q11.2. However, a number of keratin genes 
were identified within these loci. These are genes expressed in squamous and so not likely 
to be relevant in malignant progression. They seemed to be masking any potential drivers 
but further stringent filtering e.g. q value < 0.05, did not help to remove them. It appeared 
that they were being called because we had initially extended the GISTIC regions to include 
1 million base pairs up and down stream. Reducing the region to the original GISTIC loci 
successfully removed the majority of the keratin genes and reduced the gene list down to 17 
genes within the three loci (Table 7).  
Gene ID Locus 
No. of 
WT 
cases 
No. of 
amplified 
cases 
Mean 
expr in 
WT 
Mean 
expr in 
amplified Q value 
Mean log2 
fold 
change 
TCAP 17q12 116 9 0.25 1.28 1.03E-03 5.11 
STARD3 17q12 116 9 1.00 2.72 1.16E-04 2.72 
PGAP3 17q12 116 9 1.33 3.35 1.10E-04 2.51 
GRB7 17q12 115 10 1.22 2.86 9.69E-05 2.35 
MIEN1 17q12 116 9 1.23 2.73 4.79E-03 2.21 
CDK12 17q12 118 7 1.87 3.77 5.52E-04 2.02 
ERBB2 17q12 116 9 2.94 5.32 1.16E-04 1.81 
PPP1R1B 17q12 116 9 2.82 5.04 3.43E-04 1.78 
KRT17 17q21.2 113 11 1.06 2.83 9.13E-04 2.68 
LEPREL4 17q21.2 114 10 1.17 2.67 7.80E-05 2.27 
RARA 17q21.2 118 7 1.24 2.47 1.20E-03 2.00 
EIF1 17q21.2 114 10 3.34 5.71 7.80E-05 1.71 
KRT15 17q21.2 113 11 1.19 2.02 6.63E-03 1.70 
JUP 17q21.2 113 11 4.47 7.20 3.30E-05 1.61 
KRT19 17q21.2 113 11 7.78 9.54 4.64E-04 1.23 
MIB1 18q11.2 115 10 2.58 3.33 6.24E-03 1.29 
GATA6 18q11.2 113 12 3.02 3.88 2.50E-02 1.28 
Table 7 Genes with a significant difference in expression in amplified cases versus wild type cases (q 
value<0.05). 
Ordered by log2 fold change in amplified versus wild type (WT). q value<0.05 considered significant. 
(Wilcoxon Rank Sum test for p value). Expression calculated as log2(1+TPM). TPM = Transcripts Per 
Kilobase Million. 
  
Results 1: The genomic landscape of Barrett’s oesophagus  
79 
Loci 17q12 and 18q11.2 contained ERBB2 and GATA6 respectively, both known amplified 
drivers in OAC. We looked at the functions of the other genes in these 2 loci. The only two 
with apparently interesting functions were GRB7 and CDK12. GRB7 encodes a growth factor 
receptor which interacts with EGFR and promotes the activation of downstream MAP 
kinases STAT3, MAPK1 and MAPK3. CDK12 regulates transcriptional elongation and 
genes involved in DNA repair. Thereby, it is required for the maintenance of genomic 
stability. Its downregulation activates the MAPK pathway (Iorns et al., 2009). 
Locus 17q21.2 did not contain a known driver. Two genes had potentially relevant functions: 
RARA encodes the retinoic acid receptor which is a transcriptional factor with roles in cell 
differentiation and proliferation, especially known for its role in acute promyelocytic 
leukaemia (PLM-RAR translocation). JUP is a paralogue of CTNNB1 and is a junctional 
plaque protein in desmosomes and intermediate junctions (http://www.uniprot.org/ 
uniprot/P14923#function). 
We plotted the expression of amplified versus wild type cases against normal tissues 
duodenum, stomach and squamous oesophagus for each of these genes (Figure 22). The 
elevated expression of JUP and GRB7 in squamous did not make them promising drivers.  
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Figure 22 Expression of 6 significantly amplified genes in driver gene discovery 
Six genes with cancer-related functions and a significant difference in expression between amplified and wild 
type (WT) cases (q value <0.05, False Discovery Rate; Wilcoxon Rank Sum for p value), where at least 5% 
of cases have an amplification and log 2 expression > 1 in amplified samples. Log 2 expression plotted for 
each group. Comparison to expression in normal tissues. TPM = Transcripts Per Kilobase Million. 
 
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
JUP GRB7
CDK12
ERBB2
JUP GRB7
CDK12
ERBB2
0.0
2.5
5.0
7.5
10.0
●
●
●●
●
●
●
●
●
●
●
GATA6
GATA6
0.0
2.5
5.0
7.5
10.0
Group
WT
Amplified
Duodenum
Gastric
Squamous
●
●
●
●
RARA
RARA
0.0
2.5
5.0
7.5
10.0
0.0
2.5
5.0
7.5
10.0
0.0
2.5
5.0
7.5
10.0
0.0
2.5
5.0
7.5
10.0
Lo
g2
(1
+T
PM
)
Results 1: The genomic landscape of Barrett’s oesophagus  
81 
Next we examined the correlation between expression and copy number as shown in Figure 
23. The log2 expression for each sample is plotted against the log2 of CN corrected for 
ploidy. A sample with 2 copies and a ploidy of 2 will have a log2 (CN/ploidy) of 0. Each dot 
represents one sample. It is known that there is often only a weak correlation between 
amplification and expression because of the potential closed state of the chromatin. GRB7, 
RARA and CDK12 exhibited a wide variation in expression with normal copy number and 
ploidy and this did not specifically help to identify them as drivers. Two samples had a log2 
expression > 4 and more than 16 copies for ERBB2. We examined this in more detail and 
found it to be driven by SVs, with a concentration of duplications within the region of 
chromosome 17, a proportion of which were likely to be extra-chromosomal as double 
minutes (Figure 24). 
Overall, none of the four potential new drivers (JUP, GRB7, RARA, CDK12) feature in the 
COSMIC Cancer Gene Census (https://cancer.sanger.ac.uk/census) nor have been found to 
be drivers in 551 OAC cases (Frankell et al., 2019). We also showed that they were all co-
amplified with ERBB2 and not amplified independently in other samples. Given this 
evidence that they were unlikely to be drivers, and instead passengers to ERBB2 
amplification, we decided to proceed using the copy-number drivers already reported as 
amplified in OAC (Frankell et al., 2019). 
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Figure 23 Expression versus copy number of 6 significantly amplified genes in driver gene discovery 
Log2 expression for each sample plotted against the total copy number (CN) divided by ploidy. i.e. a sample 
with 2 copies and a ploidy of 2 will have a log2 (CN/ploidy) of 0. Six genes plotted: each with cancer-related 
functions and a significant difference in expression between amplified and wild type (WT) cases (q value 
<0.05, False Discovery Rate; Wilcoxon Rank Sum for p value), where at least 5% of cases have an 
amplification and log 2 expression > 1 in amplified samples. TPM = Transcripts Per Kilobase Million. 
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Figure 24 SV-driven ERBB2 amplification 
a. Scatterplot showing correlation of ERBB2 copy number and expression levels in all samples. b. Two high 
grade dysplasia cases with >16 copies of ERBB2 due to duplication structural variants. Circos plots on the left 
show positions of translocations from the ERBB2 locus. Only the SVs related to ERBB2 have been plotted. 
Histogram plots show the number of reads at the locus. 
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3.3.2 Point mutated driver genes  
We used MutSigCV and dNdScv to identify potential point mutations in driver genes in the 
cohort, i.e. mutations in genes which lead to clonal expansion and are positively selected for 
in growth of the lesion. MutSigCV identifies genes mutated more often than expected by 
chance. It uses the mutational process of neighbouring genes with similar genomic properties 
to model the background mutation rate. Whereas dNdScv uses evolutionary methods to 
detect genes under positive selection in cancer by comparing the ratios of non-synonymous 
to synonymous mutations within genes. dNdScv identified TP53, CDKN2A, ARID1A and 
PAIP2B as drivers. MutSigCV additionally identified SNTG2, SMARCA4, PTEN and 
MUC6. These genes are all known drivers in oesophageal cancer (Frankell et al., 2019). We 
did not expect to identify any new drivers because very large cohorts would be needed to 
identify low frequency driver events. But, furthermore, if a gene is not driver in OAC, it is 
unlikely to be functionally important in BE progression. 
We took these 8 genes from our discovery but also added any driver genes mutated in at 
least 10% of OACs, discovered by Frankell et al., 2019. We compared the frequency of point 
mutations/indels, amplifications and deletions of these genes across the grades in our cohort 
and observed how the driver landscape changed with progression (Figure 25). 
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Figure 25 Driver gene mutation frequency in the cohort 
Each sample is represented vertically, ordered by grade. Genes are ordered by frequency and colour coded for 
type of alteration. ND = Non-dysplastic, NP = non-progressor, PP = pre-progressor, LGD = low grade 
dysplasia, HGD = high grade dysplasia, IMC = intramucosal carcinoma. 
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CDKN2A was the most frequently altered gene, occurring in 54% of the cohort. This was 
predominantly by deletion, as found in the CN driver analysis. It was altered in a similar 
proportion of both ND and dysplastic cases (56.4% ND vs. 51.7% dysplastic). It has been 
shown to be mutated in only 29% of OAC (Frankell et al., 2019). This raises the question as 
to why there is this drop and whether clones with a CDKN2A alteration are perhaps less 
likely to expand. However, this has not been investigated here. 
TP53 was mutated in 65.0% (39/60) dysplastic cases and 0% non-progressor cases (only 
point mutations were considered and not LOH). However, a mutation was seen in one pre-
progressor case (ND). This case was examined in further detail and although all biopsies 
were graded by the histopathologist as ND in 2009, this patient had had biopsies graded as 
indefinite in 2008 and 2006, and LGD in 2005, prior to routine p53 staining. The H&E slides 
were recalled for this case and were re-graded by two senior Consultant pathologists and p53 
staining was performed. The 2005 LGD was downgraded to ND, however, there was 
significant nuclear p53 staining in the 2006 and 2008 biopsies. The 2006 biopsy was 
upgraded to LGD and the 2008 biopsy to HGD. The abnormal areas must have been missed 
on the endoscopy in 2009: highlighting the risk of sampling bias in surveillance. This patient 
was, therefore, considered as HGD and excluded from the group. It can be clearly seen that 
TP53 mutation is coincident with dysplasia (0% ND-NP, 0% ND-PP, 57.4%, LGD, 64.0% 
HGD, 71.4% IMC) (Figure 26). This is in keeping with previous work from our lab which 
compared ND and HGD samples with a gene panel and showed TP53 to be present in HGD 
(72%) and OAC (69%) but not NDBE (Weaver et al., 2014). This was the only driver gene 
for which the frequency of mutation increased stepwise with grade. In OAC wild type TP53 
cases are often affected by an MDM2 mutation, however we did not observe this here. 
Other genes which were altered at a lower frequency were also confined to the dysplastic 
stages, just not in a stepwise manner. For some drivers we saw mutual exclusivity between 
genes within the same pathways: ARID1A and SMARCA4 are both members of the SWI-
SNF family and involved in chromatin remodelling. Both were mutated in all grades, at 
similar rates to seen in cancer (Frankell et al., 2019), although ARID1A mainly by truncating 
mutations and SMARCA4 by missense mutations. ARID1A mutation was also mainly 
mutually exclusive to TP53 mutation, as has been previously described in OAC and other 
cancers e.g. (Frankell et al., 2019; Guan et al., 2011).  
GATA6 and ERBB2 amplification were also mutually exclusive and confined to dysplasia. 
However, missense mutation of ERBB2 was also seen in 16.7% ND-PP (2/12) but not ND-
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NP. Several genes were mutated in similar proportions as seen in OAC: ERBB2 alteration is 
seen in OAC (16%); GATA6 was altered in similar numbers of LGD, HGD and IMC, and 
has been shown to be mutated in 14% OAC. APC and CDK6 were also only altered in 
dysplasia. APC was altered in 11.7% (7/60) of dysplasia samples (9% in OAC) and CDK6 
in 7% (4/60) (14% in OAC). 
KRAS and MYC have both been shown to be the joint third recurrently mutated genes in 19% 
of OAC (Frankell et al., 2019). We did not see any KRAS mutations in our cohort. MYC was 
mutated in one IMC case. These genes may be important in progression to an invasive 
phenotype. 
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Figure 26 Frequency of driver gene alteration per grade 
Proportion of samples per grade with an alteration in each of the identified driver genes. ND = non-dysplastic, 
NP = non-progressor, PP = pre-progressor, LGD = low grade dysplasia, HGD = high grade dysplasia, IMC = 
intramucosal carcinoma. 
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To summarise the analysis up to this point, we considered all of the above features for each 
individual case across the cohort. Figure 27 shows the genomic and clinical features for each 
case. They are ordered by total number of SVs, detailing CNA, SNVs and numbers of 
drivers. We ordered by SV number because they had the widest variance across the cohort. 
The heatmap gives clinical and demographic information, with the first row (overall grade) 
grouping the samples into ND (grey) and dysplastic (yellow). This reiterates the findings 
above in which SVs lie on a continuum in the ND to dysplastic progression. There is an 
overall trend towards an increase in CNAs, SNVs and driver events with increasing 
dysplasia. However, an individual sample may be dominated by one genomic feature which 
tips the balance to progression to dysplasia e.g. low SV count but high % total CNA. This 
highlights the heterogeneity of progression, with many potential parallel pathways to cancer. 
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Figure 27 Summary of genomic and clinical features of the pre-cancer cohort 
All samples ordered by total number of structural variants (SV). Total copy number aberrations and mutation 
burden plotted. The heatmap details clinical features and other genomic features of each sample. The number of 
driver genes per sample plotted in pink. WGD = whole genome duplication, ND = non-dysplastic, NP = non-
progressor, PP = pre-progressor, IM = intestinal metaplasia, LGD = low grade dysplasia, HGD = high grade 
dysplasia, IMC = intramucosal carcinoma, OAC = oesophageal adenocarcinoma. 
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3.3.3 Barrett’s oesophagus adjacent to cancer (Trio BE) 
The majority of previous research using whole genome or exome sequencing has been 
conducted on non-dysplastic BE sampled from adjacent to tumour, usually from the 
oesophagectomy resection specimen (Ross-Innes et al., 2015a; Stachler et al., 2015). These 
samples represent the final stage in cancer evolution, in which large clonal expansions are 
likely. Hence it is not known to what extent the adjacent BE samples recapitulate the earlier 
time points in the natural history of the disease. Therefore, samples taken from BE adjacent 
to cancer (Trio BE) were compared with the pre-cancer BE cohort. Since the adjacent 
samples had various grades of dysplasia (38 ND, 1 indefinite, 5 LGD, 3 HGD) the ND 
samples were compared to the ND pre-cancer BE, and the dysplastic Trio BE to the 
dysplastic pre-cancer group. 
Figure 28 shows the genomic profiles comparing the pre-cancer cohort to the Trio BE. There 
was no significant difference between the median mutational burden, CNA or SV count 
when comparing the two ND groups or the two dysplastic groups (Figure 28a-c). However, 
for SVs, it was noticed that the range was wider in the Trio ND BE than the pre-cancer ND 
(Figure 28d) with some samples having SV counts similar to dysplastic samples: Trio ND 
BE SV range 2-323 (median 57); pre-cancer ND range 9-128 (median 43). Three Trio BE 
cases (6.4%) had WGD: two of which were HGD (one of which was TP53 mutant) and one 
ND (TP53 wild type). 
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Figure 28 The mutational landscape of Barrett’s adjacent to cancer compared to non-adjacent 
Box plots showing a. mutation burden, b. copy number aberrations (CNA) and c. structural variant (SV) 
burden in pre-cancer Barrett’s oesophagus (BE) and BE adjacent to cancer (Trio) split into non-dysplastic 
(ND) and dysplastic. d. SV counts for pre-cancer ND and Trio ND only. P value calculated by Wilcoxon 
Rank Sum test. ND = non-dysplastic, NP = non-progressor, PP = pre-progressor, LGD = low grade 
dysplasia, HGD = high grade dysplasia. 
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In the pre-cancer cohort, mutational signatures had been preserved across the grades, with 
signatures 17 a and b positively correlating, and signature 1 negatively correlating, with 
mutational burden. If the mutational signatures form early in the natural history of BE, and 
do not change over the course of progression, then we would expect to see a similar signature 
profile in the Trio BE adjacent to cancer. Taking only the ND Trio BE (n=39), we compared 
the mutational signatures observed with the patterns in the ND-NP and PP (Figure 29a). 
There was no difference in the mutational signature proportions in the ND Trio BE compared 
to the other ND BE. This also suggests that the tumour does not influence the mutational 
signature profile of the surrounding BE. 
The SV signatures in the ND Trio BE had a higher proportion of Signature 3 (clustered 
inversions, deletions and tandem duplications) in the samples with more SVs (Figure 29b). 
This was not seen in the pre-cancer ND samples, as they had lower SV counts. So, the ND 
Trio BE was more similar to the dysplastic pre-cancer samples, despite their benign 
phenotypic pathological appearance. 
  
 
Figure 29 Mutational and SV signature proportions in non-dysplastic BE adjacent to cancer 
compared to pre-cancer non-dysplastic BE 
a. Each mutational signature plotted as a proportion of all SNVs per sample. Total mutation burden (TMB) 
plotted above. Only pathologically non-dysplastic (ND) samples included. b. Structural variant (SV) 
signatures plotted as a proportion of total number of SVs for each case. Total SV number per case plotted 
below. NP = non-progressor, PP = pre-progressor, SBS = single base substitution. 
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In the pre-cancer cohort, we had observed the SVs to lie on a continuum across dysplasia 
grades. We therefore examined where the Trio BE cases would lie on this continuum. We 
found them to span the pre-cancer cases, irrespective of grade, falling along the whole 
continuum. Figure 30 shows, again, that the ND Trio BE can be more affected by structural 
variants than pre-cancer ND samples, and appear more genomically similar to dysplastic 
tissue. Chromothripsis was observed in two Trio BE, both ND and both wild type for TP53. 
The circos plots for these are shown below in Figure 30. The figure also highlights one ND 
Trio with 323 SVs, dominated by translocations. 
  
 
Figure 30 Structural variation continuum with Barrett’s adjacent to cancer (Trio) plotted 
Structural variant (SV) count plotted for each sample (x axis). Samples colour coded by their overall grade. 
Dysplastic Trio BE marked with a colour-coded asterisk. Circos plots shown to highlight the rearrangements 
in three ND Trio BE samples: two exhibiting chromothripsis and one with more than 300 translocations. 
Chromosomes represented around the circumference of the plot. Deletions, duplications and inversions 
marked on the inner circle, with translocations as grey lines. ND = non-dysplastic. BE = Barrett’s 
oesophagus. 
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Given the wide range of SV counts seen in the ND Trio BE, we speculated whether there 
might be a difference in the mutational profile of Trio BE cases with a similar mutation 
spectrum to its adjacent cancer and those without. We compared the mutational overlap 
between BE/tumour pairs and considered there to be overlap if >= 10% of the total number 
of BE mutations were shared (Figure 31). BE biopsies with mutational overlap with their 
adjacent tumour were not more likely to be dysplastic (p value = 0.55; Fisher’s Exact test). 
There was no significant difference between the mutational burden or SV count of BE with 
mutational overlap with adjacent tumour and BE without (Figure 32). There was a trend 
towards a significant difference in total CNAs although the median number CNAs were low: 
Trio BE with >10% shared mutations: range 0.003-26.7% (median 1.95%.); Trios with 
<10% shared mutations range 0-6.0% (median 0.69%), (p value = 0.018 Wilcoxon Rank 
Sum test). So overall, it did not appear that the more rearranged clones in adjacent BE were 
necessarily the ones from which the tumour had arisen. 
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Figure 31 Mutational overlap between Trio Barrett’s oesophagus and adjacent tumour 
Bar plot showing total number of mutations called for each Trio Barrett’s oesophagus (BE) sample and its 
adjacent cancer, and the number of mutations shared. BE samples marked with asterisks are dysplastic. 
Only BE sharing at least 10% of its mutations with the adjacent cancer was considered as an overlap. 
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Figure 32 Genomic profiles of Trio BE sharing mutations with adjacent tumour 
a. Mutation burden, b. structural variant (SV) count and c. percentage of copy number aberrations (CNA) 
plotted for Trio Barrett’s oesophagus sharing >10% mutations with its adjacent tumour and those not. P 
values calculated by Wilcoxon Rank Sum test. ND = non-dysplastic, LGD = low grade dysplasia, HGD = 
high grade dysplasia. 
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Lastly, we considered whether the driver gene alterations were occurring at different 
frequencies in the Trio ND BE compared to the NP and PP (Figure 33). Again, we considered 
only the Trio BE with ND histology (n=39) for a direct comparison and removed the TP53 
mutant ND-PP that on re-review had been from a patient with dysplasia. The CDKN2A 
alteration rate was similar to the pre-cancer ND BE, implying that it is an early event in 
progression. We found 15% (6) of the ND Trios to be TP53 mutant. This was lower than the 
rate seen in the dysplastic pre-cancer BE but it was perhaps unexpected to see it in 
phenotypically-ND samples. We also observed mutations in other driver genes that were 
otherwise only mutated in IMC or cancer: SMAD4, GATA4, KRAS. So, whilst the Trio ND 
BE overall had a similar genomic profile to ND pre-cancer BE in terms of mutation burden, 
CNAs and SVs, the driver gene profile was more similar to early cancer. It has not previously 
been shown that non-dysplastic BE next to a tumour is not representative of true ND, non-
progressing BE.  
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Figure 33 Driver gene alteration frequencies in only the non-dysplastic Barrett’s adjacent to cancer 
Proportions of driver genes with amplification, deletion or point mutations in non-dysplastic non-progressor 
samples, pre-progressor samples and from BE adjacent to cancer. 
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 Summary 
We created a carefully-curated cohort of BE samples, representing the grades from non-
dysplastic through to IMC, for genomic sequencing. This was with the aim of elucidating 
the key biological processes driving Barrett’s oesophagus (BE) to progress to oesophageal 
adenocarcinoma (OAC). This is the first whole genome sequencing focussing on the 
different grades of disease progression, and with long follow-up. Whilst, overall, we 
observed a significant increase in median mutation burden and percentage CNAs between 
ND and dysplastic samples, the ranges were wide. Analysis did not reveal a clear separation 
between either the overall grades of the patients or the actual grades of the biopsies 
sequenced. It has previously been shown that non-dysplastic BE is highly mutated, with 
similar mutation rates to OAC (Ross-Innes et al., 2015a) so it is perhaps unsurprising that 
there was little change in the mutation burden with progression through the grades. Total % 
CNAs, in contrast, was low for ND samples but had a wide variation for dysplastic cases: 
with some IMC samples displaying very few CNAs. We noticed that, in these cases, a high 
number of structural rearrangements were present instead, potentially explaining the 
phenotype seen. Total SV number per sample had the biggest variance within grades. 
Although there were no defining genomic features separating NP and PP samples, analysis 
of expression data may reveal differences. 
Placing all the samples in order of their total SV count revealed a clear continuum from ND 
to dysplastic samples which was consistent with the morphological grade and clearer than 
using other genomic features. HGD and IMC samples had the highest burdens of SVs. 
Structural variants in BE have not been widely studied because of the need for whole genome 
sequencing and this progression with grade has not previously been observed. Signatures 5 
(clustered translocations) and signature 2 (unclustered tandem duplications) were seen 
across all grades. Whereas signature 3 (clustered deletions, inversions and tandem 
duplications) was mainly observed in dysplastic samples with high SV burdens. In some 
cases, SVs were driving some of the CNAs that we were seeing e.g. ERBB2 amplification. 
The next step will be to perform an in-depth analysis of regions recurrently affected by SVs 
which may reveal new, or higher frequencies of, driver genes in progression. It would also 
be very interesting to build a larger cohort of non-progressors and pre-progressors with 
multiple timepoints to track how the SV count changes over time and observe how early we 
see these large-scale alterations.  
Results 1: The genomic landscape of Barrett’s oesophagus  
101 
An analysis of driver events in the grades confirmed a stepwise increase in frequency of 
mutation of TP53 with grade. We did not see TP53 mutation in the ND-PP samples. This is 
in keeping with previous work from our lab (Weaver et al., 2014) but contrasts a recent study 
which used a gene panel on NP and PP and found a 46% TP53 mutation rate in the pre-
progressors (Stachler et al., 2018). GATA6, ARID1A and APC, although mutated at lower 
frequencies, were confined to dysplasia and not seen in ND biopsies. ARID1A mutation was 
mutually exclusive with TP53 mutation. We did not see any differences between the long-
term ND-NP cases and the ND cases that went on to progress. This suggests that the 
mutations and rearrangements that are accumulate with progression are not there at the early 
stages. However, we appreciate that only one biopsy was sequenced per case, so we do not 
necessarily get a complete insight. 
The analysis of ND BE sampled from adjacent to cancer (Trio BE) had a similar mutational 
burden and proportion of copy number aberrations to non-progressor and pre-progressor BE. 
It has previously been assumed that ND tissue from adjacent to cancer would be genomically 
similar to ND-NP but this has previously neither been confirmed or refuted. Whilst the TMB 
and CNAs did not differ, a number of Trio BE samples had very rearranged genomes and a 
higher frequency of driver gene alterations, otherwise not seen at the ND stage. This 
highlights the likelihood of an initial field cancerisation, which has been widely described, 
or, furthermore, the possibility of the surrounding BE being altered by the presence of the 
tumour. The BE adjacent to cancer, therefore, should not be compared to pre-cancer non-
progressing BE and, in these cases, the histology is misleading. 
Overall, the findings confirm the heterogeneity of BE oesophagus. No specific, recurrent 
molecular features define the assigned phenotypic, pathological grades. Instead, BE appears 
to be more a continuum of disease. Plotting all the features of all samples per case suggests 
that there are multiple paths to cancer: one dysplastic sample may have a dominance of 
structural rearrangement and another may have more focal CNAs. 
Given the mutation burden and clonal/origins of BE metaplasia, it is an interesting point of 
discussion as to whether the histology of metaplasia is misleading and if BE should be 
regarded as a neoplasia instead. However, the inability of most BE to progress/grow 
counteracts this and one could argue that the terminology fits the clinical trajectory. 
This heterogeneity makes finding biomarkers to diagnose progression difficult. Using cut-
offs of burdens of molecular features may prove to be more useful than panels of specific 
molecular features and this shall be explored further in Results 4. 
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4. Results 2: The transcriptomic landscape of Barrett’s 
oesophagus 
 
Aim 1: Elucidate the key biological processes driving Barrett’s oesophagus (BE) to progress 
to oesophageal adenocarcinoma (OAC) by performing an integrated analysis of genomic and 
transcriptomic sequencing of the individual grades of BE. 
• Analyse the differential expression of genes in non-dysplastic versus dysplastic 
Barrett’s oesophagus in order to identify recurrent expression changes in progression. 
• Perform pathway analyses for up- and downregulated genes to understand the key 
processes occurring in progression. 
• Compare how the immune composition of the biopsy correlates with grade. 
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 Sample comparison of the most variably expressed genes 
Of the samples that had undergone WGS, 93 Barrett’s oesophagus (BE) samples (25 non-
dysplastic (ND) non-progressors (NP), 10 ND pre-progressors (PP), 12 low grade dysplasia 
(LGD), 25 high grade dysplasia (HGD) and 21 intramucosal carcinoma (IMC) had sufficient 
quantities and adequate qualities to undergo whole transcriptome sequencing. In addition, 
we sequenced 31 BE adjacent to cancer (Trio BE) and 80 normal tissues as a comparison 
(18 duodenum (D2), 38 normal oesophagus (NE) and 24 gastric cardia (GC)). 
After performing batch correction using ComBat, group comparisons were made by 
calculating the 1000 most variably-expressed genes and performing a principal component 
analysis (PCA). Firstly, considering only the normal tissues, they formed distinct groups of 
samples which confirmed that the sequencing was of good quality (Figure 34a). One gastric 
sample clustered with squamous and vice versa. Pathology records did not suggest 
contamination and they had not been extracted on the same day or plated on the same batch. 
Secondly, PCA demonstrated that neither batch nor RNA integrity number (RIN) were 
confounding factors (Figure 34b, c). 
  
 
Figure 34 Principal component analysis of all normal tissue and all samples by batch and RIN 
a. All normal tissues. Percentage of variability explained by each principal component (PC) displayed in 
parentheses. b. All samples coloured by batch. c. All samples coloured by RNA Integrity Number (RIN). 
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On considering all the samples, the squamous phenotype contributed predominantly to 
principal component (PC) 2 (Figure 35a). This was not surprising as squamous epithelium 
has a very different expression profile to the glandular epithelium of BE, gastric and 
duodenum. In order to better observe the separation of the other groups, we repeated the 
PCA excluding the squamous. BE samples, regardless of dysplasia status, formed a 
distinctive group which, surprisingly, was distinct from duodenum with PC2. There was 
some overlap of BE with gastric samples but it was mainly the Trio BE rather than the pre-
cancer BE (Figure 35b,c). This could be because they contained gastric metaplasia (GM), 
whereas we were careful to exclude samples with GM when creating the pre-cancer BE 
cohort. 
 
  
 
Figure 35 Principal component analysis of all samples 
a. All samples coloured by group. b. Squamous excluded from the analysis, coloured by overall group. c Same 
plot as in b. with BE samples further coded by grade. ND = non-dysplastic. PC = principal component. 
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Next we focussed in on how well the pre-cancer ND and dysplastic BE would cluster 
independently. PCA of the 1000 most variable genes between ND and dysplastic BE 
separated the pre-cancer BE cohort well on PC2 but not so much so on PC1 (Figure 36a). 
This was surprising however may possibly be explained by the overall composition of frozen 
biopsies and the presence of inter-mixed ND epithelium within dysplastic biopsies. Whilst 
the highest cellularity biopsies possible were used, this would be unavoidable without 
microdissection. 
We used the same 1000 genes to compare the Trio BE to the pre-cancer cohort. The Trio BE 
scattered throughout the pre-cancer cohort, rather than clustering independently (Figure 
36b). When coloured for their grade many of the Trio BE that had been graded pathologically 
as ND clustered with the pre-cancer dysplastic samples (Figure 36c). This finding was 
consistent with the genomic patterns seen in Results 1. It seems that although pathologically, 
BE adjacent to cancer looks like ND non-progressing BE, neither the genomic nor 
expression profiles convey this. 
  
 
Figure 36 Principal component analysis of Barrett’s oesophagus samples 
a. Trio BE samples excluded. Colour coded by overall dysplasia status. b. Trio BE included. c. Trio BE 
included but coded by their dysplasia status. ND = non-dysplastic. 
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 Differential gene expression analysis 
4.2.1 Expression in dysplastic versus non-dysplastic 
In order to understand the changes in gene expression with progression we compared the ND 
and dysplastic samples of the pre-cancer BE cohort by performing a differential analysis 
using DESeq2 (Love et al., 2014b). When considering a differential expression of greater 
than 3-fold (log2 fold change (FC) > 1.58) there were 352 significantly upregulated genes 
and 123 significantly downregulated (q value < 0.05) in dysplastic versus ND samples 
(Supplementary table 1) (Figure 37). Given the heterogeneity of BE, a fold change of 3 was 
chosen to avoid small magnitude changes that would unlikely be biologically significant. 
 
  
 
Figure 37 Volcano plot of differentially expressed genes between dysplastic and non-dysplastic 
Genes with expression greater than 3-fold change difference (log2FC > 1.58 or <-1.58) and q value < 0.05 
coloured in red. Vertical dashed lines represent the FC cut offs. Horizontal dashed line marks the q-value 
threshold for significance. Outlier genes individually labelled. 
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The extreme log2FC of 30 in KRTAP9-7 was driven by a very high expression in one sample. 
(530 vs. a median of 0 for other samples). It was expressed in one other dysplastic case at a 
low level but not in any other dysplastic or non-dysplastic cases. This one high count was 
enough to contribute to the significant fold change which DESeq2 computes. KRTAP9-7 is 
a keratin-associated protein only expressed in skin, (http://www.uniprot.org/uniprot/A8M 
TY7#function). It was not expressed in the squamous samples in our cohort and it is not 
expressed in other cancers (http://www.proteinatlas.org/ENSG00000212659-KRTAP9-
6/pathology). Given that it was only expressed in one sample it was not considered to be 
relevant and likely from contamination. 
In order to understand more about the biological processes in progression, rather than 
focussing on specific outliers, we looked at the gene deregulation as a whole and the 
pathways involved. 
4.2.2 Significantly deregulated genes in dysplasia 
Using the significantly up- and downregulated genes between ND and dysplastic, from the 
DESeq2 output, we compared the expression across the samples. Firstly, we considered only 
the pre-cancer cohort and found the ND and dysplastic cases to cluster distinctly with 
hierarchical clustering (Figure 38). However, there was no distinct clustering of the grades 
(non-progressors (NP), pre-progressors (PP), LGD, HGD, IMC) either by taking the patient 
grade or the dominant grade in the biopsy. Although HGD (orange) and IMC (red) did 
dominate the right of the hierarchical clustering dendrogram. The NP (blue) and PP (purple) 
samples were indistinguishable, although this is not necessarily surprising as one would not 
expect expression changes to occur so far in advance of phenotypic change and they were 
genomically similar in Results 1.  
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Figure 38 Clustered heatmap of expression of up or downregulated genes in the pre-cancer Barrett’s 
oesophagus cohort 
Each row represents a significantly up or downregulated gene (in dysplasia compared to ND) from the DESeq2 
output. The columns are samples. Expression is scaled for each gene using the Z-score (subtracting the mean 
and dividing by the standard deviation). High expression is red, low expression is blue. The dendrogram at the 
top shows the hierarchical clustering (using the ward D method) of the samples. The horizontal annotation 
bars show the overall grade of the patient, the biopsy subgrade and the patient subgrade. ND = non-dysplastic, 
ND-NP = non-dysplastic non-progressor, ND-PP = non-dysplastic pre-progressor, LGD = low grade 
dysplasia, HGD = high-grade dysplasia, IMC = intramucosal carcinoma. 
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In Results 1, there was no significant difference in the median numbers of mutations, copy 
number aberrations or structural variants between the Trio BE and the pre-cancer BE. In 
order to see if there was any difference at the expression level, we added the expression of 
the above genes in the Trio BE. We found that the Trio BE samples were a mix of the patterns 
seen in pre-cancer ND and dysplastic samples, irrespective of the grade of the Trio BE 
(Figure 39). ND Trio BE both genomically and transcriptomically behaved more like 
dysplasia despite its indolent phenotypic appearance. Some Trio BE cases appeared to have 
upregulation of dysplasia genes, whilst still expressing the ND genes. This strengthened the 
finding we had seen in the earlier PCA and also in the genomic analysis in Results 1. 
The Trio BE were labelled as dysplastic if they pathologically had any dysplastic cells at all 
in the frozen specimen. Thus, the percentage of dysplasia was generally lower than in the 
pre-cancer cohort. This could explain the expression of ND genes in the dysplastic Trio BE, 
but not the opposite: seeing the expression of the dysplasia genes in the ND samples. So, the 
ND Trio BE appears to have a different expression profile which is in a hybrid state between 
ND and dysplastic cases. 
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Figure 39 Unclustered heatmap of expression of up or downregulated genes in the pre-cancer Barrett’s 
oesophagus cohort compared to the Trio BE. 
Each row represents a significantly up or downregulated gene (in dysplasia compared to ND) from the DESeq2 
output. The columns are samples ordered by grade. Expression is scaled for each gene using the Z-score. High 
expression is red, low expression is blue. The horizontal annotation bars show the overall grade of the patient 
or the biopsy grade. Grade of the Trio BE samples is coded in the second horizontal annotation bar. ND = non-
dysplastic. 
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Lastly, we took the significantly up and downregulated genes and compared their expression 
in the pre-cancer BE samples to the normal squamous oesophagus, gastric cardia and 
duodenum in order to ascertain whether they were expressed in normal tissue or specific to 
BE (Figure 40). This differed to the prior comparison in Figure 35 of the most variably 
expressed genes across all tissue types. Some of the differentially expressed genes were 
strongly expressed in squamous tissue. These genes were expressed in a small number of BE 
samples and this was likely due to squamous contamination. However, this was enough to 
drive the significant expression differences seen in the analysis. 
Excluding the squamous genes, the genes expressed in the ND samples (downregulated in 
dysplasia) were also highly expressed in duodenum (Figure 40). The intestinal metaplasia of 
Barrett’s oesophagus has a phenotype similar to duodenal tissue, with pathognomonic goblet 
cells, and so this would not be unexpected. However, these genes were not expressed in the 
dysplastic samples, suggesting some loss of this intestinal phenotype with progression. In 
contrast, the genes upregulated in dysplasia were not strongly expressed in any of the normal 
control tissues. 
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Figure 40 Heatmap of pre-cancer Barrett’s oesophagus samples compared to the normal tissue 
Each row represents a significantly up or downregulated gene (in dysplasia compared to ND) from the DESeq2 
output. The rows are clustered hierarchically using the ward D method. The columns are samples ordered by 
grade and normal tissue type: duodenum, gastric, squamous. Expression is scaled for each gene using the Z-
score. High expression is red, low expression is blue. 
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To further evaluate this, we took all the genes with upregulation of expression in both NDBE 
and duodenum from the analysis (82 genes) and compared the overall expression of these 
genes between the grades and all tissue types.  
The mean Z-score for these genes was calculated for each patient and these means compared 
for each group. Figure 41 shows that the genes expressed in duodenum are also expressed in 
NDBE, but that this expression is significantly lower in dysplastic tissue (p=5.1x10-13, 
Wilcoxon Rank Sum). As expected, these genes are hardly expressed at all in gastric and 
squamous samples. In the earlier PCA, in Figure 35, the most variable genes between all 
samples were considered and, overall, the BE was more similar to gastric. Instead, this 
differential analysis was considering only the differential genes between dysplastic and ND, 
rather than tissue similarity. So, the genes which are downregulated in the transition from 
ND to dysplastic are predominantly also expressed in duodenum. 
 
Figure 41 Downregulation of intestinal phenotype with progression 
Boxplot of mean expression of genes upregulated in duodenum per sample. All genes were taken from the 
differential expression analysis that were expressed highly in duodenum. Z-score calculated for every sample 
for each gene and a mean was taken of the Z-scores of all genes per sample. This gave a proxy value for the 
overall expression of duodenal genes for each sample. Mean values plotted as a boxplot for each group. P-
values calculated using Wilcoxon Rank Sum test. 
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In order to understand more about the functions of the downregulated genes, we ran 
Ingenuity Pathway Analysis (IPA; Qiagen, Germany) and stringDB (https://string-db.org). 
The most significant Gene Ontology terms for molecular and cellular functions were lipid 
metabolism and molecular transport, digestion and intestinal absorption (e.g. CDX1). 
APOBEC1, involved in the editing of cytosine to uracil and usually only expressed in small 
intestine, was in the cluster. The top predicted regulator effect network included HNF4A and 
HNF1A. These are transcription factors which are thought to be important in the 
development of the intestines, liver and kidney (https://www.ncbi.nlm.nih.gov/ 
gene?cmd=Retrieve&dopt =full_report&list_uids=3172). IPA also showed them to interact 
with three other upstream regulators, resulting in a complex network of gene regulation 
involved with glycolysis and transport of molecules (Figure 42). PPARG encodes a nuclear 
receptor with roles including the controlling the peroxisomal beta oxidation pathway of fatty 
acids and gut homeostasis via suppressing NF-kappa-B-mediated proinflammatory 
responses (http://www.uniprot.org /uniprot/P37231#function). A number of the genes e.g. 
APOB, MTTP, FABP1, FABP2 are involved specifically in lipid transport, a main function 
of the small intestine. The loss of genes involved in lipid transport is consistent with the loss 
of phenotype seen with progression. 
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MUC2, encoding the secretory protein mucin-2, was significantly down-regulated from ND 
to dysplasia. It is a goblet cell marker specific to duodenum, small intestine, colon and 
rectum (https://www.proteinatlas.org/ENSG00000198788-MUC2/tissue). It is known to be 
a marker for intestinal metaplasia in BE (Lavery et al., 2014; Reis et al., 1999; Zhou et al., 
2019b). We separately considered the expression of 2 other genes known to be goblet cell 
markers: TFF3 and REG4. They were not found to be differentially expressed in the DESeq2 
analysis because there was a <3-fold difference between the dysplastic and ND. However, 
all three showed a significant reduction in expression with progression, with very low 
expression in gastric and squamous. These findings are also in keeping with the concept of 
a loss of intestinal phenotype with progression. 
 
 
Figure 43 Expression of goblet cell markers in different tissue types 
Boxplots showing expression (log2(1+TPM)) of goblet cell markers in non-dysplastic (ND) versus dysplastic 
Barrett’s oesophagus compared to normal tissues. Trio = BE adjacent to cancer. P-values given between ND 
and dysplastic (Wilcoxon Rank Sum test). TPM = transcripts per kilobase million. 
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Overall, the genes which are downregulated in the progression from ND to dysplastic, were 
found to be normally expressed in duodenum but not gastric or squamous. They are 
predominantly involved in normal intestinal functions including absorption, secretion and 
lipid metabolism. On histology, we see a loss of intestinal metaplasia with progression (Naini 
et al., 2016; Odze, 2006) and the expression data supports this. 
  
Results 2: The transcriptomic landscape of Barrett’s oesophagus  
119 
 Pathway analysis of differentially-expressed genes in pre-
cancer dysplasia 
Next we focussed on the genes upregulated in the dysplastic samples. In order to see if these 
genes grouped into pathways, we again used Ingenuity Pathway Analysis (IPA). All the 
significantly up and downregulated genes in dysplasia, with a fold change >3 were inputted. 
An upstream analysis identified 126 of the genes as being downstream of the mitogen-
activated protein kinase (MAPK/ERK) pathway. The MAPK pathways have long been 
known to have roles in the regulation of cell proliferation, apoptosis and differentiation 
(reviewed in (Burotto et al., 2014; ZHANG and LIU, 2002)). These genes and their 
interactions are shown in Figure 44. Some of the downstream genes in the pathway, e.g. 
CXCL1, CXCL2 and IL8 encode chemokines or other genes important in the immune 
response (highlighted in pink in Figure 44). CXCL1 is a chemoattractant of neutrophils in 
inflammation and CXCL2 is produced by activated monocytes and neutrophils. IL8 (also 
called CXCL8) encodes a chemokine secreted by macrophages. It was not possible to say if 
there was upregulation of these genes because of the MAPK pathway or because there was 
increased inflammation. However, the pathology reports of the biopsies did not indicate a 
difference in inflammation between the dysplastic and the ND samples. Alternatively, the 
immune environment may independently facilitate progression, which is further explored 
later in this chapter.
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Figure 44 Interactions of all genes downstream of the ERK network 
Visual representation of the interactions between the 126 genes altered in my cohort which are downstream of 
regulators in the ERK network. Genes highlighted in pink are also in the ‘Immune System’ Reactome Pathway. 
Intensity of grey line represents strength of data support. Generated using the STRING database (https://string-
db.org). 
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Fifteen of these genes are directly regulated by ERK1/2 (Figure 45a). The mechanistic 
network function in IPA predicted the activation or inhibition of 20 upstream regulators of 
these genes (Figure 45b). 
 
  
 
Figure 45 The MAPK pathway 
a. Fifteen genes directly regulated by ERK. Genes shaded in red are upregulated in our analysis. The shape of 
the icon represents protein function. b. Ingenuity Pathway Analysis prediction of all upstream regulators in the 
MAPK pathway. Upstream of the 126 genes in Figure 44. Genes predicted to be activated or inhibited based 
on the expression of the downstream genes in the samples in the Barrett’s oesophagus cohort. Predicted 
activation = orange, predicted inhibition = blue. 
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This analysis indicates upregulation of the MAPK pathway in dysplasia. However, this effect 
could have been driven by high expression in a small number of samples. To consider this, 
a heatmap was plotted of the expression of just these 126 genes. In Figure 46a the samples 
are sorted by patient grade but the genes in the rows are hierarchically clustered. 89 of the 
126 genes were upregulated in the differential analysis, indicated in red in the first vertical 
annotation bar, and the rest were downregulated. The vertical annotation bar gives the IPA 
prediction as to whether the observed expression would be due to activation or inhibition of 
the upstream pathway. The majority of the labels are green in the upregulated genes, 
indicating overall pathway activation. The predictions are given by IPA, using inbuilt 
literature review information, and should only be used as a guide. They are also simplified 
as only the dominant prediction was used across multiple regulators. The heatmap shows 
that the upregulation does occur across all the dysplastic samples and is not seen in the ND. 
In contrast, there is upregulation of a small number of genes in the ND which inhibit the 
pathway and have loss of expression with progression. 
To strengthen these findings, we looked at the overall upregulation of genes in the pathway 
per sample and compared each grade. To do this we took only the upregulated genes and 
calculated the mean Z-score for each sample as a proxy for the overall activation. Figure 46b 
shows a significant overall upregulation of the pathway in the dysplastic cases (p = 4.5x10-
12, Wilcoxon Rank Sum test). There was a significant increase from ND-PP to LGD, but no 
significant difference between the dysplastic grades (Figure 46c). 
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Figure 46 Expression of genes downstream in the ERK/MAPK pathway 
a. Heatmap of the scaled expression of the 126 genes downstream of ERK in the non-dysplastic (ND) and 
dysplastic Barrett’s oesophagus. Clustering of genes in the rows (ward D). Rows scaled using Z-score. Samples 
in the columns ordered by grade. First vertical annotation bar indicates if the gene was up (red) or down (blue) 
regulated in dysplasia in the differential analysis. The second bar is the Ingenuity Pathway Analysis prediction 
of whether the expression seen would lead to activation (green) or inhibition (blue) of the MAPK pathway. b. 
c. Boxplot representation of the overall MAPK pathway upregulation. Z-scores calculated for each gene across 
the samples. A mean Z-score was then calculated for each sample as a proxy for the overall representation of 
the pathway in the sample. Mean scores plotted per group. P values calculated between groups (Wilcoxon Rank 
Sum test). ND-NP = non-dysplastic non-progressor, ND-PP = non-dysplastic pre-progressor, LGD = low grade 
dysplasia, HGD = high-grade dysplasia, IMC = intramucosal carcinoma. 
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Gene set enrichment analysis corroborated the above findings, with enrichment of genes in 
the AP1 (FOS/JUN) pathway (Schaefer et al., 2009) that acts immediately downstream of 
ERK1/2 (Figure 47). 
  
 
Figure 47 Gene set enrichment analysis of the AP1 pathway 
AP1 (FOS/JUN dimer) is activated by ERK in the MAPK pathway. All genes from the differential analysis 
used with their calculated fold changes. List of genes curated by GSEA based on the literature (Schaefer et al., 
2009). 
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This analysis only considered genes which were found to be significantly deregulated in 
dysplasia vs. ND in the DeSeq2 analysis. It is important to consider any genes in the pathway 
which were not deregulated. Furthermore, many of the genes identified as being downstream 
in the network are also downstream in other pathways. We used an independent published, 
curated list (Ünal et al., 2017) of direct targets of ERK and considered the expression of 
these 246 genes in the pre-cancer cohort using hierarchical clustering Figure 48. 
  
 
Figure 48 Expression of direct downstream targets of ERK 
Heatmap of gene expression, in the pre-cancer cohort, of a published, curated list of 248 direct downstream 
targets of ERK. Hierarchical clustering of non-dysplastic (ND) and dysplastic Barrett’s oesophagus in columns, 
and genes in the rows (ward D). Rows scaled using Z-score. 
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The heatmap shows increased expression of the genes in the main cluster of dysplastic 
samples, on the left of the heatmap. The differential expression is less clear as with the earlier 
gene set from IPA, but that is expected given that the previous gene set was sampled from 
genes that had been confirmed to be differentially expressed. Overall this analysis supports 
the above findings, that there is overall upregulation of the ERK/MAPK pathway in 
dysplasia. 
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 Immune infiltration in progression 
4.4.1 Introduction 
With the fast expansion of large data sets of bulk RNA sequencing, computational methods 
have been developed to analyse the complete immune infiltrate. Gene Set Variation Analysis 
(GSVA) is a tool which assigns immune enrichment scores to samples based on the 
expression of different immune markers (Hänzelmann et al., 2013). This allows the 
deconvolution of the expression data to predict the proportions of each immune cell type 
within the sample. We were interested to look at the composition of the immune 
microenvironment as it is becoming increasingly clear in cancers that the tumour 
microenvironment (TME) can impair anti-tumour immunity by polarising the immune 
composition towards less cytotoxic subsets e.g. T regulatory cells (Lin et al., 2016). T 
regulatory cells have a suppressive role in normal physiology by regulating the activation 
and expansion of T and B cells. In the tumour setting this can result in reduced anti-tumour 
immunity due to inhibiting cytotoxic T cells and the secretion of immunosuppressive 
cytokines. Increased cytotoxic T cell infiltrations are associated with an increased mutational 
burden but improved survival in OAC (Noble et al., 2016; Secrier et al., 2016). The 
infiltration of another immune cell type, M2 macrophages, is promoted by Th2 cytokines. 
They are characterised by their anti-inflammatory cytokine production resulting in a pro-
tumorigenic effect. Increased proportions of these tumour-associated macrophages have 
been shown to be associated with poor prognosis in squamous oesophageal carcinoma 
(Sugimura et al., 2015). 
A number of clinical trials of immune modulators e.g. PD-1 inhibitors are currently 
underway in oesophago-gastric cancer. PD-L1 can be expressed by tumour cells, which 
interacts with PD-1 on effector T cells and suppresses the T cell response. Nivolumab, an 
anti-PD1 inhibitor, was found in the Phase III ATTRACTION-2 trial of advanced gastric 
and gastro-oesophageal cancers, in an Asian population, to offer a survival benefit versus 
placebo (Kang et al., 2017). These have been combined with CTLA-4 inhibitors and have 
been shown to be superior in combination to a PD-1 inhibitor alone in Phase II studies, but 
with significant side effects (CheckMAte-032 Study) (Janjigian et al., 2018). 
The roles of the immune cells in the progression of Barrett’s through the dysplastic stages is 
less well understood. An increased Th-2 cytokine profile (IL-4, IL-10) and CD4+ T cells in 
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non-dysplastic Barrett’s compared to inflamed squamous oesophagus has been described 
(Fitzgerald et al., 2002; Moons et al., 2005). However, these profiles were similar in 
duodenal biopsies (Lind et al., 2012) suggesting that it may be the presence of intestinal 
metaplasia phenotype causing the shift in immune infiltrate. T regulatory and dendritic cell 
(DC) densities have been shown to increase in dysplasia but maturation of these DCs may 
be impaired by factors secreted by the Barrett’s mucosa (Somja et al., 2013). 
4.4.2 Immune deconvolution 
We used GSVA to compute the immune cell compositions of the samples. As with the 
previous analysis, there were several possible ways to group the biopsies for comparison. 
The overall grade of the patient, irrespective of the composition of the actual biopsy, or the 
highest grade captured in the biopsy could be used. As the biopsy grade is harder to be certain 
of with frozen tissue, we firstly used these enrichment scores to compare the overall patient 
grades, as we had done above and for the genomic features in Results 1. However, the 
proportions of immune cell groups by patient grade did not change significantly with 
progression. So, we then considered the immune compositions based on the highest grade 
within the biopsy and found significant differences. Firstly, considering the myeloid lineage: 
we observed a significant decrease from ND to LGD in immature dendritic cells (p value < 
0.01) and a trend to a decrease in neutrophils (Figure 49). Both of these cell groups then 
increased with progression through the dysplasia grades, with a significant rise in neutrophils 
from LGD to HGD/IMC. Neutrophils are attracted to the TME by chemokines secreted by 
the tumour cells and they can have both pro- and anti-tumour roles (reviewed in (Galdiero 
et al., 2013).  
A similar pattern was seen in some of the lymphoid lineages: T regulatory cells, B cells and 
NK CD56dim cells (Figure 50). Cytotoxic T cells did not change significantly. There were 
no significant increases from HGD to IMC, however the IMC group was small because few 
samples pathologically contained IMC. 
These findings were in keeping with previous pre-sequencing work in BE, which, in 
particular, have observed a failure of maturation of DCs (Somja et al., 2013), supporting the 
increasing proportions of immature DCs which we observed. 
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Figure 49 RNA enrichment scores for myeloid immune cell types by biopsy grade 
Enrichment scores plotted by biopsy grade for immune cell types in the myeloid lineage. iDC = immature 
dendritic cells. IM = intestinal metaplasia, LGD = low grade dysplasia, HGD = high grade dysplasia, IMC = 
intramucosal carcinoma. The Y axis scale is variable for each cell type. Significant p values are marked with 
asterisks: * = p value < 0.05, ** = p value < 0.01, ** = p value < 0.001, Kruskal-Wallis test. 
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Figure 50 RNA enrichment scores for lymphoid lineage immune cell types by biopsy grade 
Enrichment scores plotted by biopsy grade for immune cell types in the lymphoid lineage. Tcm = T central 
memory, Tem = T effector memory, Tfh = T follicular helper cells. IM = intestinal metaplasia, LGD = low 
grade dysplasia, HGD = high grade dysplasia, IMC = intramucosal carcinoma. Y axis scale variable for each 
cell type. Significant p values marked with asterisks: * = p value < 0.05, ** = p value < 0.01, Kruskal-Wallis 
test. 
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Finally, we performed hierarchical clustering using these enrichment scores to see if, overall, 
there was a change in proportions of cells in progression, when considering all immune cell 
groups. The grades did not cluster together, but the clustering did highlight two groups within 
the cohort: those with a higher immune infiltration (across both myeloid and lymphoid 
lineages) and those with lower (Figure 51). Increased cytotoxic T cell infiltrates are 
associated with an increased mutational burden and improved survival in OAC (Noble et al., 
2016; Secrier et al., 2016) and increasing CNAs have been shown to correlate with reduced 
expression of markers of CD8+ T cells (Davoli et al., 2017). Using the clustering 
dendrogram we classified the samples as being either immune high or low and calculated 
the total mutation burden and % CNA for each sample. However, we did not observe any 
correlation between immune infiltration and numbers of alterations in this cohort. 
  
Results 2: The transcriptomic landscape of Barrett’s oesophagus  
132 
  
 
Figure 51 Hierarchical clustering on immune cell type from expression data 
Hierarchical clustering of pre-cancer cohort by immune cell enrichment scores, calculated using Gene Set 
Variation Analysis. Dendrogram splits samples into low and high immune infiltration. Bar charts beneath show 
mutation burden and copy number aberration percentage for each sample. NK = Natural killer, DC = Dendritic 
cell. ND = non-dysplastic, NP =non-progressor, PP = pre-progressor, LGD = low grade dysplasia, HGD = high-
grade dysplasia, IMC = intramucosal carcinoma. 
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 Summary 
We performed bulk RNA sequencing on 125 Barrett’s samples and analysed the expression 
differences seen between non-dysplastic and dysplastic samples. A differential analysis 
identified 475 deregulated genes. The expression of these genes clustered ND from 
dysplastic samples well. However, we did not observe individual clustering of the grades of 
dysplasia. 
BE with intestinal metaplasia (IM) shares a number of intestinal phenotypic features with 
duodenum, but also has functional similarities to the pyloric glands of the stomach. Overall, 
on consideration of the most variably-expressed genes between these three tissue types, BE 
split distinctly from both, supporting the incomplete intestinal metaplasia of BE. However, 
when we considered only the genes that were differentially expressed between ND and 
dysplastic BE, we found that more than two thirds that were downregulated in progression 
were highly expressed in duodenum. This included specific genes which are expressed in 
goblet cells, TFF3 and MUC2, which have previously been shown to be good biomarkers of 
BE (McIntire et al., 2011; Ross-Innes et al., 2015b). Histologically, we observe a reduction 
in IM in dysplastic tissue (Naini et al., 2016; Odze, 2006) and these results support this 
observation: with progression to dysplasia there is a downregulation of expression of genes 
that convey the IM phenotype. Clinically, TFF3 staining sensitivity has been shown not to 
be reduced in the higher grades when used as a biomarker (Ross-Innes et al., 2015b). So, 
this loss of IM phenotype is an important finding biologically but would not necessarily 
affect BE biomarker design because the genes are still expressed in dysplasia, just at a lower 
level.  
A previous microarray study considered the ‘intestinal-like signature’ that they saw in BE 
and found it to persist in OAC (Duggan et al., 2016). However, very small numbers of normal 
tissues were used to form the signature (3 squamous oesophagus, 3 colon, 3 duodenum). We 
did not see this preservation in dysplasia however, it would be interesting to compare the 
expression of our gene signature in OAC too. 
Pathway analysis of the genes downregulated from ND to dysplastic identified HNF4A as a 
regulator effect network. HNF4A encodes a transcription factor that is usually found in 
primitive intestinal cells in embryonic development. It has recently been shown to induce 
chromatin opening in normal oesophagus cells resulting in a Barrett’s-like chromatin 
signature (Rogerson et al., 2019). The downregulation of this network in dysplasia would fit 
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with the loss of the IM phenotype. A previous recent whole transcriptome study had findings 
that, on first look, do not seem in keeping with our results. They found HNF4A to be 
upregulated in OAC and expressed (but at a lower level) in NDBE (n=14 ) and LGD (n=8) 
(Maag et al., 2017). However, they mainly compared OAC (n=12) to normal squamous 
oesophagus (n=17), rather than GC or D2. It fits that all the glandular tissues had higher 
expression of HNF4A than squamous tissue. In our analysis, although comparisons were 
between the dysplasia and ND, we did not see upregulation of HNF4A itself. A comparison 
of our data to OAC may help to resolve this. 
We observed a much higher number of significantly upregulated genes with progression 
(352) than those downregulated (123). In particular, there was a significant increase in 
expression of a number of genes downstream of the ERK/MAPK pathway. This pathway 
has previously been shown to be activated in BE cell lines by acid exposure (Jaiswal et al., 
2006; Morgan et al., 2004; Souza et al., 2002). Several members of the cascade e.g. EGFR, 
MYC and KRAS and have been shown to be amplified in OAC, both in historic studies 
(e.g.(Sommerer et al., 2004)) and recent genomic studies (Frankell et al., 2019). However, 
in Results 1 we only observed MYC to be amplified in one dysplastic sample. AP1 
(FOS/JUN), a transcription factor also downstream in the ERK/MAPK pathway, has been 
implicated as a key regulator of expression in OAC (Britton 2017). Most studies of these 
pathways have been on cell lines or microarrays on small numbers of human samples. 
Paterson et al. compared gene expression in NDBE, dysplasia and OAC using microarrays 
but found the MAPK pathway enrichment in NDBE and dysplasia to be the same, and only 
enrich further in OAC, when using a small number of genes (Paterson et al., 2013). Our 
results indicate that the upregulation of the pathway is important in the transition from a ND 
to dysplastic phenotype, which has not previously been shown. The important next step will 
be to look at the methylation of the genes in this pathway as this is likely to explain the 
changes in expression. If recurrently hypomethylated promotors can be identified, then it 
may be possible to derive a biomarker from this. It would also be necessary to perform 
functional experiments to prove this with cell lines. 
In the immune analysis of the expression data, we found that the immune composition 
depended more on the specific grade of dysplasia surrounding the immune cells rather than 
the overall patient grade. This is different to the genomic analysis, where a field effect 
seemed to occur. The three immune cell types which best correlated with progression 
through the grades of dysplasia were neutrophils, T regulatory cells and immature dendritic 
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cells. All of which have been shown to have roles in tumourigenesis (reviewed in (Togashi 
et al., 2019; Tran Janco et al., 2015)). 
In the differential analysis we showed CXCL1 expression to be significantly higher in 
dysplasia, which may explain the observed increase in neutrophils. Hepatocellular 
carcinoma cells have been shown to secrete chemokines which attract neutrophils. The 
neutrophils, themselves, secrete pro-angiogenic proteins which promoted progression 
(Kuang et al., 2011). A number of other studies have also shown neutrophils to have pro-
tumourigenic properties (reviewed in (Tecchio et al., 2013)) but this has not been studied in 
the progression of BE. 
For all three immune cell types (neutrophils, T regulatory cells and immature dendritic cells) 
we observed an initial reduction from ND to LGD, with significance reached (p < 0.001) for 
iDCs. These findings need to be validated in larger cohorts by IHC. We attempted a new 
multiplex IHC technique which allows the simultaneous analysis of multiple immune types 
from one tissue cut. However, it was unsuccessful in this cohort because the small biopsy 
cuts lost adherence to the slide and washed away. Instead, we need to focus on the 3 immune 
cell types that had significant changes and perform traditional IHC separately for each of 
them. 
It would also be interesting to look at larger resection samples composed of multiple grades 
and compare the immune composition to grade within a sample. Furthermore, the iDC levels 
need to be compared to mature DCs and, whilst there was no overall change in the numbers 
of macrophages, the ratio of M1/M2 macrophages has been shown to be important in cancer 
progression and this should also be looked at in future work.  
In the genomic analysis, the samples followed a gradual continuum with progression. In the 
expression analysis we observed a similar gradual progression of increasing expression when 
performing a principle component analysis. However, when we grouped genes to analyse 
specific pathways, we observed more of a distinction between the expression in non-
dysplastic versus dysplastic samples. Overall, it would seem that the continuum of SNVs, 
CNAs and SVs leads to a continuum of expression changes. We hypothesise that when this 
altered expression is for genes that fall into the same pathway, the balance is tipped, the 
pathway is upregulated, and progression occurs. 
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5. Results 3: Clonal heterogeneity in Barrett’s oesophagus 
 
Aim 2: Consider the heterogeneity and clonal evolution of BE segments and how this may 
influence progression. 
• Examine the genomic heterogeneity within Barrett’s oesophagus segments. 
• Use clonal and subclonal mutations and copy number alterations to understand the 
clonal evolution of Barrett’s oesophagus. 
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 Introduction 
In cancer, the importance of intra-tumoural heterogeneity (ITH) as well as heterogeneity 
between tumours is becoming increasingly recognised. If different clones within the tumour 
respond differently to therapy then the degree of ITH may affect treatment choice and can 
determine therapeutic response and survival e.g. (Jamal-Hanjani et al., 2017; Murugaesu et 
al., 2015). ITH has also been shown to be important in pre-invasive disease. Maley et al. 
calculated a diversity score in BE using: aneuploidy and tetraploidy, by flow cytometry; loss 
of heterozygosity of the loci containing CDKN2A and TP53 using fluorescent in-situ 
hybridisation (FISH); and CDKN2A and TP53 mutation (Maley et al., 2006). They showed 
that increased clonal diversity at baseline could predict the risk of progression to cancer. 
More recently, a single cell analysis using a panel of FISH probes also found the baseline 
diversity to predict progression (Martinez et al., 2018). Next generation sequencing has not 
widely been used to study the diversity within BE, but this approach would enable a more 
extensive analysis without a priori knowledge or assumptions about which loci are likely to 
be informative. Multilevel WES has previously been performed on five patients with 
Barrett’s adjacent to cancer  to look at the clonal relationship of the cancer to BE (Stachler 
et al., 2015). A lot of heterogeneity was observed, in that not all BE biopsies from a given 
patient were clonally related to the tumour (as we observed in our analysis in Results 1: 
3.3.3). Two of the five patients had missense TP53 mutations in all their biopsies. This 
clonality led them to speculate that TP53 mutation may occur prior to dysplasia: earlier than 
previously thought. They also observed oncogene amplification confined to individual 
biopsies, suggesting that it may be a later phenomenon. In a previous study from our 
laboratory, WGS with further targeted amplicon sequencing was used for an in-depth 
analysis of a single patient with IMC (Ross-Innes et al., 2015a). This study found evidence 
for an initial clonal sweep with dysplasia developing from multiple different clones. 
Together, these studies confirm the heterogeneity of BE, and suggest that a single biopsy 
from a BE segment does not represent the whole lesion. To date, studies have focussed on 
either a few specific events or on BE adjacent to cancer. The dynamics of the complete 
genomic landscape across a segment have not been studied in detail. We also do not know 
whether the structural variation follows the same patterns of heterogeneity as the SNVs and 
CNAs. In our WGS, we focussed on using the highest grade possible within the segment, 
with the best cellularity in order to compare grades between patients. Here we aimed to 
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elucidate how these biopsies related to their surrounding BE, and how grade and distance 
affected this. 
 Multilevel cohort selection 
In order to study the intralesional heterogeneity in our cohort, multiple levels were sequenced 
from a subset of patients in my overall BE cohorts. Specifically, 15 additional levels from 6 
cases were included, for which further good quality frozen biopsies were available 
(containing a good percentage of glands and no squamous, but irrespective of grade). Figure 
52 details these cases. The overall grade of the patient and highest grade seen within each 
individual biopsy are given. All biopsies were taken at the same time as, or within 6 months 
of, the previously-sequenced biopsies as it was felt that there would be unlikely to be any 
genomic changes in such a short period. This gave us 3-4 levels per case. 
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Figure 52 Whole genome sequencing of multilevel cases 
Frozen biopsies taken from multiple levels of 6 cases identified for whole genome sequencing to give 21 
levels in total. For each patient the overall grade at that timepoint, age, sex, maximum length of BE and 
smoking status is given in the heading. Images depict levels (distance from the incisors in cm) at which 
biopsies were taken and the pathological grade of the biopsy. Indefinite for dysplasia means that the biopsy 
was difficult to grade. GM = gastric metaplasia, IM = intestinal metaplasia, LGD = low grade dysplasia, 
HGD = high grade dysplasia, IMC = intramucosal carcinoma, yo = years old.  
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 Genomic features of the multilevel cases 
Firstly, the total mutation burden (TMB), copy number aberration (CNA) and numbers of 
structural variants (SVs) between biopsies taken from single individuals were compared. 
Figure 53 shows this for each of the 6 cases. Each case presented a very different profile. 
The TMB ranged from 0.24-15.1 mutations/Mb; median 7.0. This variation was irrespective 
of the grade composition of the biopsy. In cases 1,4 and 6, all the biopsies from a given 
individual had similar profiles. In contrast, case 2, 3 and 5 showed more variation across 
biopsies. This diversity was also very noticeable when looking at the CN profiles of 
individual cases (Figure 54). For example, whilst the biopsies in case 6 have similar total % 
of genomes with CNAs, the profiles are heterogeneous. 
 
Figure 53 Genomic features of the multilevel cohort 
Biopsies from individual cases are grouped, with the overall grade and the levels from which the biopsies taken 
in cm. The colour of each bar represents the highest grade of BE within that biopsy. The 3 bar charts give 
measurements mutation burden, total % of genome altered by CN and total number of structural variants. GM 
= gastric metaplasia, IM = intestinal metaplasia, LGD = low grade dysplasia, HGD = high grade dysplasia, IMC 
= intramucosal carcinoma, CN = copy number, SV = structural variant. 
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Figure 54 Genome wide copy number profiles of multilevel cases 
Genomic copy number profiles from the Battenberg output for each biopsy. Case number and overall grade of 
the patient are indicated above each set of plots. Biopsy ID and grade are detailed above individual plots. 
Chromosome number is listed along the plot from 1 to X. Yellow lines represent the total copy number of each 
region, grey lines represent the B allele frequency. GM = gastric metaplasia, IM = intestinal metaplasia, LGD 
= low grade dysplasia, HGD = high grade dysplasia, IMC = intramucosal carcinoma. 
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We next considered the proportions of each mutational signature contributing to each biopsy 
and found that, on the whole, there was preservation of the proportions mutational signatures 
between biopsies from a case (Figure 55). Where heterogeneity did occur e.g. case 1, the 
biopsies that were different did not match those that stood out as different with the genomic 
features above (mutation burden, total CNA, SV count). 
  
 
Figure 55 Mutational signatures in the multilevel cases 
The proportions of each mutational signature contributing to biopsies relative to the total mutation burden. 
The upper plot shows proportions of each signature within the total mutation burden. The lower plot shows 
the overall proportions of each signature. Known aetiologies of the signatures are given in parentheses 
(https://cancer.sanger.ac.uk/cosmic/signatures). HGD = high grade dysplasia, IMC = intramucosal carcinoma, 
SBS = single base substitution. 
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The SV signature profiles were also generally preserved within cases (Figure 56). However, 
where there was variation, this too was not concordant with the variability of the genomic 
features. Biopsies in case 4, which had similar genomic profiles, also had similar SV 
signature proportions and mutational signature proportions. However, in case 1, the four 
biopsies had similar genomic profiles, but biopsy B had a different SV signature pattern, 
with signatures 1 and 2 present but an absence of SV signatures 3 and 4. Furthermore, two 
different mutational signature profiles were seen in first two versus the second two biopsies. 
Other cases had similar SV signature proportions despite the genome-wide CN profiles 
above looking very different e.g. cases 2 and 3. 
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Figure 56 Structural variant signatures in the multilevel cases 
The proportions of each SV signature contributing to biopsies relative to total number of SVs. Upper plot 
shows proportions of each signature within the total SV count. Lower plot shows the overall proportions of 
each signature. HGD = high grade dysplasia, IMC = intramucosal carcinoma. 
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Lastly, we considered the SNV and CN driver gene mutation events and how the biopsies 
compared (Figure 57). Driver events were identified in 19/21 biopsies. No driver event was 
identified in biopsy 1C, despite containing IMC. As above, the heterogeneity was marked, 
but patterns could be seen when comparing the driver gene profiles to the CN alterations 
shown in Figure 54. For example, biopsies 1A and 5B are TP53 mutant and have a very 
different genomic CN profile to their neighbouring wildtype biopsies. 
Focussing on TP53 mutations specifically, in 2 of the 6 cases missense mutations in TP53 
were seen in all the biopsies (cases 3 and 4). In case 4, all biopsies had the same position 
TP53 SNV: p.R273C a TP53 hotspot. However, in case 3 only 2 of the biopsies shared the 
same TP53 mutation position. This suggests that TP53 mutation was an early event in these 
cases, and before WGD as this was only observed in 3A. 
Case 5 only has a TP53 mutation in biopsy B: so, in this case TP53 mutation must have 
occurred later. This biopsy was also the only one to have undergone WGD. Interestingly, 
Biopsy 3B was described pathologically as gastric metaplasia, yet it had a TP53 mutation. 
Gastric metaplasia alone is considered indolent with almost no risk of progression. TP53 
was also mutated in the IM biopsy 4A. Case 6, was clinically unusual because on endoscopy 
there appeared to be 4 distinct areas of IMC. In terms of SNV, CNV and SV numbers, there 
was little difference between the 4 biopsies. The genomic CN profile highlighted somewhat 
more variation. However, the heterogeneity became most clear when considering the driver 
events: with GATA6, PTEN, ERBB2 and MYC mutations seen in different biopsies. The 
TP53 and ERBB2 mutations were the same positions in the 3 biopsies they were in. 
WGD was called in 7/21 biopsies. In three patients it was only in one of the biopsies, 
suggesting that it may have been a late event.  However, in case 4, all four biopsies exhibited 
WGD, indicating that it may have occurred earlier and led to the expansion of a single clone. 
Overall, the timing of TP53 mutation in these cases was variable: an early event in some 
cases and late in others. However, WGD was generally a later event and only occurred in 
the TP53 mutant biopsies. This fits with our WGD analysis in Results 1. However, the 
pathway to cancer appears to be more complicated than the model suggested by Stachler et 
al. (Stachler et al., 2015). In their analysis of BE adjacent to cancer, they observed early 
TP53 mutation and WGD. We observe there to be more variation than this, in particular the 
observation of TP53 mutation and WGD in only one of the dysplastic biopsies within a 
segment. 
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Figure 57 Driver mutations in the multilevel cases 
Single nucleotide variants, amplifications and deletions in known driver genes per biopsy. Asterisks identify 
mutations in same genomic positions across biopsies from a single case. Patient grade in headings, biopsy 
grades colour coded, with lettering referring to the biopsy ID. Only driver genes with mutations are listed. 
Driver gene list as used in Results 2. Any excluded genes are not mutated. Whole genome doubling (WGD) 
noted above biopsies. GM = gastric metaplasia, IM = intestinal metaplasia, LGD = low grade dysplasia, HGD 
= high grade dysplasia, IMC = intramucosal carcinoma. 
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  Clonality analysis 
The next aim was to analyse the clonality of the cases in order to construct phylogenetic 
trees. To do this, all pre-filtered calls for SNVs and their positions were analysed to see if 
the mutations were shared between biopsies. The overall number of SNVs called, and the 
degree of overlap, varied vastly from case to case (Figure 58). The four dysplastic biopsies 
in case 1 (HGD) had similar numbers of SNVs and % of genome altered by CNAs between 
them in the above analysis, yet only 1.2% of the mutations were shared between all the four 
biopsies (median number SNVs 9,503; range 9,362-11,636). Conversely, case 4, also HGD, 
had 4 biopsies ranging from IM to HGD. The median number of SNVs per biopsy was higher 
at 21,514 (range 20,566-22,200) and 81.7% of this median (17,578 SNVs) were seen in all 
four cases.  
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DPClust v2.2.5 (Nik-Zainal et al., 2012a) was used to model clonal expansions by 
calculating the cancer cell fraction (CCF) of each mutation. This is the proportion of tumour 
cells (in this case BE cells) in which the variant is present. Estimating the CCF depends on 
the local CN and the cellularity (proportion of BE cells in the biopsy). A variant with a CCF 
of 1 means that it is in all the ‘cancer’ cells and is considered clonal, whereas any variants 
with CCFs < 1 are subclonal. 
Figure 59c shows scatterplots of pairs of biopsies from Case 4. For each SNV the CCF in 
one biopsy is plotted against the CCF in the other biopsy. The clonal cluster can be seen at 
the coordinates x =1, y=1. Case 4 has a clear clonal cluster shared by each biopsy, comprising 
18,969 mutations (pink cluster 16 in Figure 59d). This gave rise to 2 divergent subclones: 7 
(390 mutations) and 12 (628 mutations) (Figure 59e, f). These each gave rise to two further 
subclones, resulting in unique subclones within each of the four biopsies. Clusters with fewer 
than 1% of the total number of mutations were excluded. 
Case 1, in contrast, had minimal sharing of variants and no common ancestral clone. 
Subclone 12 (6768 mutations) was present with a CCF of 1 in biopsies C and D (Figure 60c). 
Subclone 2 was seen in biopsy A and subclone 4 in biopsy B. This meant that there was no 
common clone from which all BE cells arose, which in this case, does not fit with the idea 
of there being an initial clonal expansion.  
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Figure 59 Case 4 clonality analysis: all subclones arising from one common ancestral clone 
a. Demographics, biopsy levels and pathology. b. Venn diagram of overlap of SNVs. c. DPClust output 
showing paired biopsy comparisons of cancer cell fractions (CCF) of each SNV. CCF on the x and y axis, 
with clonal cluster at 1,1. d. DPClust assignment of cluster to SNVs based on CCF. e. Cluster output and 
number of mutations in each cluster. CCF for each biopsy. Clusters with <1% of the total number of mutations 
are filtered out. f. Phylogenetic tree construction based on the cluster CCF per biopsy in e. IM = intestinal 
metaplasia, LGD = low grade dysplasia, HGD = high grade dysplasia. 
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Figure 60 Case 1 clonality analysis: distinct, unrelated clones  
a. Demographics, biopsy levels and pathology. b. Venn diagram of overlap of SNVs. c. DPClust output showing 
paired biopsy comparisons of cancer cell fractions (CCF) of each SNV. CCF on the x and y axis, with clonal 
cluster at 1,1. d. DPClust assignment of cluster to SNVs based on CCF. e. Cluster output and number of 
mutations in each cluster. CCF for each biopsy. Clusters with <1% of the total number of mutations are filtered 
out. f. Phylogenetic tree construction based on the cluster CCF per biopsy in e. IM = intestinal metaplasia, LGD 
= low grade dysplasia, HGD = high grade dysplasia, IMC = intramucosal carcinoma. 
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Figure 61 shows the trees constructed for the other three cases analysed for clonality. All 
biopsies in cases 2 and 3 arise from a common clone. Whereas case 5 is complicated: clone 
2 (17,567 mutations) is clonal in biopsy B, but not present in A or C. However, clone 4 
(3061) is clonal in A and C and subclonal in B. This could possibly be explained by clones 
converging. 
 
Figure 61 Phylogenetic trees for multilevel cases. 
Trees constructed using the cancer cell fraction of clusters of mutations defined by DPClust. Patient 
demographics and grade given in headings, with age, sex, maximum Barrett’s length and smoking status. Venn 
diagrams as in Figure 58. Phylogenetic tree construction based on the cluster CCF per biopsy. 
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 Summary 
We analysed the intralesional heterogeneity of 6 dysplastic BE segments by performing 
WGS on multiple levels from each case. It has previously been shown with using more 
targeted variant analyses that BE segments are likely to be polyclonal and have a high degree 
of intralesional heterogeneity. However, this has not been evaluated on a cohort of patients 
using WGS. WGS is perhaps more suited to this purpose than WES or mutation panels 
because intronic passenger mutations are key in clonal and subclonal analyses. This is likely 
to be particularly true in BE, which is highly mutated but, unlike most cancers, carries fewer 
clonal mutations. 
The 6 multilevel cases highlighted just how heterogenous BE is, with each case needing to 
be considered completely independently. However, within cases, the total mutation burden, 
total % of genome with CNAs and total numbers of SVs were surprisingly constant between 
biopsies, irrespective of grade. This is reassuring because in earlier analyses we used the 
overall patient grade over the grade of the actual biopsy. On the whole, mutational and SV 
signature proportions were preserved between biopsies from a case, supporting their early 
formation. More heterogeneity was observed when considering the driver gene events, WGD 
and patterns of genome-wide CNAs, indicating these to be later events. This may suggest 
that the overall burdens of the different genomic aberrations are determined by the local 
environment and exposure to specific mutagens, and so there is a consistency between 
biopsies. But the specific genes disrupted are stochastic. This leads to the development of 
multiple clones which are heterogeneous mainly because of their spectrum of driver gene 
alterations i.e. driver gene alterations drive the heterogeneity observed within a BE segment. 
Five of the cases underwent a clonality analysis. Only 3 of the 5 cases had a common 
ancestral clone, from which all subclones were derived. This may imply that BE does not 
always originate with an initial clonal sweep, or, after the sweep, completely new, 
independent clones can arise within the segment. We observed clear heterogeneity between 
biopsies for CN, driver gene mutations and WGD. In order to understand more about the 
clonal evolutionary paths in the progression of BE, future work needs to include multilevel 
non-dysplastic cases to compare the heterogeneity seen and include both non-progressor and 
pre-progressor cases. Furthermore, the construction of formal phylogenetic trees, with the 
number of mutations represented by the length of the branch, and driver mutation annotation, 
will be informative regarding the time between clonal sweeps and the key mutations 
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involved. A divergence score, adapted from those previously published, needs to then be 
applied. Divergence could then be correlated with progression. 
We were surprised to see such a high mutation burden in the gastric metaplasia (GM) biopsy 
of case 3, when considering all of the unfiltered calls (30,854). In the genomic analysis, we 
had used the filtered Strelka variant calls, which had called 9681 SNVs. We looked at the 
variant allele frequencies (VAFs) of this sample which showed that 14,202 of the variants 
had a VAF < 0.05, and so had not been called by Strelka. This may be because a GM biopsy 
is of lower cellularity and would be similar to sequencing normal stomach: there would 
unlikely be many high VAF mutations. These low VAF mutations overlapped with another 
biopsy, raising the possibility that Strelka may be missing some of these. However, in calling 
these, a lot of background noise would likely also be called. We used stringent filters in our 
genomic analysis in order to be highly confident of our calls. We do not have further GM 
samples to compare to because we avoided sequencing them. Overall, we did not see this 
problem of low VAF calls with other samples: for the other two biopsies in case 3, one had 
417 mutations with a VAF < 0.05 and the other had 702. 
Finally, one key advantage of WGS is that the structural variation within a biopsy can be 
analysed. We performed only a superficial SV analysis, considering count and SV 
signatures. For future work, an in-depth comparison of the SV types, and specific genes 
affected between clones would give further information about the timing of these events. 
DPClust does not take SVs into account. SVClone is a computational method for inferring 
the cancer cell fraction of structural variant breakpoints from whole-genome sequencing data 
(Cmero et al.). It would be interesting to use this tool and compare it to the clonality estimates 
made using SNVs and CN. 
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6. Results 4: The Clinical Implications 
 
Aim 3: Identify how the biological findings may be integrated with clinical information in 
order to categorise patients of high and low-risk of progression. 
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 Introduction 
The molecular characterisation in the above chapters suggests a continuum of changes, 
punctuated by some key events, which correlate with advancing grade of disease. This gives 
us an increased understanding of the biology of progression, but the next step is to apply this 
information clinically to identify high-risk individuals. Whilst dysplasia is currently the 
gold-standard for identifying patients at high-risk of progressing to cancer, it is not perfect. 
Its diagnosis can be subjective, especially in the presence of inflammation. LGD is especially 
difficult to grade and there is significant inter-observer variability (Duits et al., 2015). 
Furthermore, although we treat all patients with confirmed dysplasia, only 11.6%/year of 
patients with LGD will progress to cancer (Phoa et al., 2014). So, the aim is to identify which 
combination of molecular features can best identify the high-risk individuals. 
 Decision tree 
One way of categorising patients into risk groups would be a decision tree using multiple 
features. A decision tree has an advantage of being simple and easy to follow. We used a 
supervised learning algorithm (rpart package) with 16 features from genomic, expression 
and clinical data (Table 8) to grow a classification tree. The algorithm requires full data for 
each variable so smoking and body mass index could not be included, although they are 
known to be risk factors for BE. 87 samples had complete clinical information for inclusion. 
The genomic and expression features were all calculated using the same methods as used in 
the earlier chapters (see Methods). 
Genomic 
statistics 
Driver gene 
mutation 
status 
Clinical 
features 
Other events Expression 
Total mutation 
burden 
TP53 Age Chromothripsis Chromosomal 
instability signature 
Total copy 
number change 
CDKN2A Maximum BE 
length/cm 
Whole genome 
doubling 
 
Total SV count ERBB2 
   
Ploidy GATA6 
   
 
ARID1A 
   
 
SMARCA4 
   
 
MUC6 
   
Table 8 Features used for decision tree design 
SV = structural variant, BE = Barrett’s oesophagus 
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The algorithm splits the data recursively, until the end criterion of dysplasia status is reached. 
At each split, it determines which individual variable will give the largest possible reduction 
in heterogeneity of the dysplasia status. The variable which best split the data was the total 
structural variant (SV) count with a cut-off of 79 SVs, calculated by the algorithm, followed 
by TP53 mutation status, then the proportion of the chromosome instability (CIN) signature 
(cut-off >0.38) to classify the remaining samples (Figure 62). Previously, the focus has 
always been on the correlation of SNVs and CNAs with dysplasia grade (Gu et al., 2010). 
SVs have not been considered, likely because non-WGS sequencing methods could not call 
them. This algorithm found SVs to discriminate better between the grades than TMB or 
CNA. This fits with our genomic analysis which showed a good discrimination between ND 
and dysplastic and a gradual increase in SV burden with progression. 
  
 
Figure 62 Decision tree model using rpart in R 
The tool considered which of 16 features could best classify the samples by dysplasia status.SV = structural 
variant, CIN = chromosomal instability, ND = non-dysplastic, Dysp = dysplastic. 
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The CIN signature was able to further classify 4 dysplastic samples as being at risk. 
However, clinically, it would be advantageous to focus on one sequencing modality. We 
decided to reapply the clinical model using only SV count and TP53 mutation status. This 
also meant that all 99 samples could be used, rather than only those with DNA and RNA 
sequenced. We then looked at all the other clinical and genomic features for the patients 
falling into each group to see if outliers displayed any distinguishing characteristics that were 
not in the initial model. One of the strengths of this cohort is that we have collated a 
comprehensive clinical annotation, including follow-up with future treatment and outcome. 
Figure 63 summarises all of this information with a decision tree and heatmaps for each of 
the four classifications. Group 4 samples (low SV count, TP53 wild type) would be 
considered low risk, groups 1-3 would be considered high-risk. The top bar of the heatmap 
denotes the overall grade of the patient (grey/yellow). As expected, the majority (87%) of 
the ND patients are in group 4. However, 8/42 in this group are dysplastic (3 LGD, 4 HGD, 
1 IMC). We looked at these cases in more detail to see if there were other features to suggest 
that they were at risk. 
Of the 8 outlier dysplastic cases in the low-risk group, notably, 4 were female, a far higher 
ratio than seen in BE. However, there was no statistically significant difference between the 
male:female ratios in group 1 (high SV count, TP53 mutant) versus 4 (p value = 0.15, 
Fisher’s exact test). None of the cases in the low risk group had whole genome duplication 
(WGD). The specific features of each of these outlier cases are detailed in Figure 64. All 8 
patients were smokers but there were no other unifying features. Four of the 8 cases had a 
driver event in a gene other than CDKN2A (which is commonly mutated in NDBE). One 
case had a high mutation burden, greater than the median mutation burden in OAC (6.4 
mutations/Mb ) (Frankell et al., 2019). Potentially, these driver gene alterations could be the 
cause of progression or it may be another feature that we have not yet considered e.g. a gene 
affected by a specific SV. We noticed that 3 of the 8 dysplastic patients had an ARID1A 
alteration. Of the other 34 low risk patients, only 3 had an ARID1A alteration. Across the 
whole 99 pre-cancer BE patients there were 14 ARID1A alterations in total. 12 of which were 
in TP53 wild type biopsies, suggesting a degree of mutual exclusivity. There was only a 
trend to significance: p value = 0.040 (Fisher’s Exact Test) but this highlights the possibility 
of an alternative pathway to progression. 
We reviewed the pathology consensuses of these cases. Firstly, of the frozen biopsies 
sequenced: seven had at least two of three pathology reviews agreeing on the presence of 
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dysplasia. However, one of the LGD cases, when further reviewed had a consensus of there 
not being any dysplasia within the frozen section. This may explain it falling into the low-
risk category. The clinical FFPE block pathology reviews and follow-up were then checked 
for each of these cases. They all had at least 2 endoscopies on which dysplasia was confirmed 
and all had endoscopic treatment of the dysplasia, suggesting that these were definitely 
samples from patients who had progressed to dysplasia at the time they were taken. 
Lastly, one possible explanation could have been that these samples were of lower cellularity 
and so the pipelines struggled to call the mutations. However, the computational cellularity 
was not significantly lower in these cases compared to other dysplastic cases (p value = 0.97, 
Wilcoxon Rank Sum). There was no significant difference between groups 1 and 4 for 
smoking status, age or length of BE. 
One must consider the caveat of comparing to the gold standard of dysplasia. There is a 
possibility that the model has correctly identified these patients as low risk. The difficulty 
we have is that the patients were treated at the point of a diagnosis of dysplasia, so we do 
not know if they would have gone on to progress further. 
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Figure 63 Classification decision tree using structural variant burden and TP53 mutation status 
Classification of 99 Barrett’s oesophagus (BE) samples by structural variant (SV) burden followed by TP53 
mutation status (mut = mutant, wt = wildtype). SV count cut-off calculated by rpart algorithm. Cohort divides 
into 4 groups. Groups 1-3 considered high-risk and group 4 considered low risk. For each group, copy number 
aberrations (CNA) and total mutation burden (TMB) plotted. Clinical features and other genomic features 
displayed in heatmap annotation. WGD = whole genome duplication, IM = intestinal metaplasia, ND = Non-
dysplastic, NP = non-progressor, PP = pre-progressor, LGD = low grade dysplasia, HGD = high grade dysplasia, 
IMC = intramucosal carcinoma, OAC = oesophageal adenocarcinoma. 
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Figure 64 Clinical and genomic characteristics of dysplastic cases classified in the low risk group 
Maximum length of BE segment given in cm. Circos plots show SVs for each case. TMB = total mutation 
burden, CNA = copy number aberrations, WGD = whole genome duplication, SV = structural variant, wt = 
wildtype, LGD = low grade dysplasia, HGD = high grade dysplasia, IMC = intramucosal carcinoma. 
 
Results 4: The Clinical Implications  
164 
The five non-dysplastic outliers in high-risk groups 2 (high SV count, TP53 wild type; 2 
ND-NP, 2 ND-PP) and 3 (low SV count, TP53 mutant; 1 ND-PP) were also investigated 
further (Figure 65). Of the two non-progressor cases, the 63-year-old male had 10 years of 
ND pathology on endoscopy. Four years before the sequenced biopsy and 6 after. This gives 
us confidence that he is truly a long-term non-progressor. He remains under surveillance. 
The 59-year-old male had a total of 13 years of surveillance. However, the biopsy which was 
sequenced was taken at his most recent surveillance in 2017 so there is the possibility that 
he may go on to progress in the future. 
There were 3 pre-progressor cases categorised in the high-risk group. A 57-year-old male 
who progressed to LGD 2y 2m later. A 70-year-old male who actually had a clinical 
diagnosis of indefinite for dysplasia at the sequenced timepoint. He progressed to HGD on 
an endoscopy 1 year 3 months later. And a 55-year-old female, with a TP53 mutation, who 
also had a diagnosis of indefinite for dysplasia on her endoscopy in 2008. She then had LGD 
3.5 years later in 2012, followed by HGD 6 months after. Of course, with knowing the 
follow-up, we can see that these 3 cases were high-risk cases at this point, and perhaps, the 
decision tree correctly classified them. However, it classified the other ND-PP as low risk. 
Overall, for a clinical test, overcalling a small proportion of cases, as above, is not such an 
issue, but the sensitivity is key so that patients with the disease are not missed. Using 
dysplasia grade as the gold-standard, SVs (>79 cut-off) and TP53 mutation has a specificity 
of 87.2% and a sensitivity of 86.7% for its diagnosis. In comparison, when classifying the 
cohort using only TP53 mutation, the specificity was excellent (98%), but the sensitivity 
dropped to 65%. This finding is in keeping with previous studies which used TP53 mutation 
as a biomarker in BE (Ross-Innes et al., 2017). SVs alone had a similar specificity of 89.7%, 
and a sensitivity of 75%. 
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Figure 65 Clinical and genomic characteristics of non-dysplastic cases classified in the high-risk group 
Maximum length of BE segment given in cm. Circos plots show SVs for each case. TMB = total mutation 
burden, CNA = copy number aberrations, WGD = whole genome duplication, SV = structural variant, wt = 
wildtype, NA = not available, ND = Non-dysplastic, NP = non-progressor, PP = pre-progressor. 
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As a comparison, we used the same criteria on the Trios BE (BE adjacent to cancer) and the 
adjacent cancers (Figure 66). The model only captured 24/47 of the BE cases (2 HGD, 4 
LGD, 18 ND). The low risk group comprised of 1 HGD, 1 LGD, 1 indefinite for dysplasia 
and 20 ND. Whilst this highlights the findings in Results 1 and 2, that not all BE Trio samples 
act like their grade, the model only was able to classify 47% of the non-dysplastic samples. 
This raises the issue of the heterogeneity that we see in BE and a risk stratification test like 
this would not omit the need for multiple biopsies to be taken. In contrast, the model 
classified 46/47 (97.9%) of the OAC samples as high risk. 
 
  
 
Figure 66 Classification of BE adjacent to cancer using the decision tree 
Forty-seven BE samples adjacent to cancer (Trios) classified using the clinical decision model of TP53 
mutation status and structural variant (SV) count. The pathology of each specific biopsy is given; however, 
all biopsies were taken at the cancer timepoint. ND = Non-dysplastic, NP = non-progressor, PP = pre-
progressor, LGD = low grade dysplasia, HGD = high grade dysplasia. 
 
TP53 mutant?
Yes No
SV count >= 79
94 samples:
47 Trios BE (Barrett’s adjacent to cancer),
47 Trios OAC
48 46
Yes No Yes No
43 5 22 24
1 HGD, 3 LGD, 2 ND,
37 OAC
4 ND, 1 OAC 1 HGD, 1 LGD,
12 ND, 8 OAC
1 HGD, 1 indefinite,
1 LGD, 20 ND, 1 OAC
High risk Low risk
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 Summary 
We show that the structural variant count coupled with the TP53 mutation status can be used 
risk stratify BE samples into high and low-risk groups. SV burden has not previously been 
evaluated.  
A clinical risk stratification model for progression to HGD was recently published, assigning 
points for smoking (5 points), BE length (1 point/cm), male sex (9 points) and confirmed 
LGD on endoscopy (11 points) (Parasa et al., 2018). A score of >20 was considered to confer 
a high-risk of progression (2.1%/yr). All three of the LGD cases that fell into our low-risk 
class would score as high-risk in this model, mainly given the weighting of points for LGD. 
However, we assume that a LGD patient is misgrouped if they fall into the low risk category, 
even though they might never have progressed to HGD. This again highlights the difficulty 
with comparing to the current gold-standard of dysplasia. A caveat of their model is that it 
relies on both accurately sampling the LGD area on endoscopy and correctly diagnosing it. 
Both of which are difficult to do. It also cannot take into account the potential regression of 
LGD which was seen in 27.9% of patients in the SURF trial during the follow-up period 
(Phoa et al., 2014). This is an inherent confounder which is difficult to resolve now that 
patients are treated at the LGD stage and not followed-up for further progression. 
From our 5 ND patients that fell into the higher risk groups, only 1 was high-risk using the 
Parasa et al. model but 3 were considered to be of intermediate risk. Adding smoking status 
to our model would have moved the dysplastic outliers into a higher risk category. However, 
8 ND-NP and 5 ND-PP were also smokers in the low risk group so this would increase the 
false positive rate. 
Whole genome sequencing for every patient with BE is not currently a viable option, mainly 
due to cost but also because it requires fresh/frozen tissue. However, if there are specific 
regions recurrently affected by SVs, it might be possible to then only sequence a portion of 
the genome and look for the breakpoints, especially if they are clustered. These regions are 
mainly fragile sites e.g. containing FHIT and WWOX and can be very large. FHIT is more 
than 1.5 million bp; WWOX 1.1 million. However, baits could be designed to pull out these 
whole regions for sequencing. Reducing the proportion of the genome being sequenced 
could facilitate a move to working with FFPE tissue: the current method of clinically 
preserving tissue. 
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Another problem is that the model still relies on the right tissue being sampled at endoscopy. 
We saw in our clonality analysis that there is a lot of heterogeneity between individual 
biopsies from a BE segment. The focus from here would be to test our model on a prospective 
cohort, more representative of the surveillance population, to see if the sensitivity and 
specificity hold on a less curated sample set. 
If we are able to focus in on specific genomic regions, we could sequence to a higher depth. 
These methods could then be applied to much lower cellularity samples and, potentially, to 
non-endoscopic cell sampling devices such as the Cytosponge samples. 
New sequencing methods, e.g. Nanopore technology (Oxford Nanopore Technologies, UK) 
may also make such an approach more practical. Nanopore sequencers can produce read 
lengths of up to 2Mb, without size selection, limited only by sample quality and library 
preparation method. In doing this it maps the breakpoints directly rather than using the 
unmapped reads, and provides a quick and easy method for SV detection (Sakamoto et al., 
2019). 
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We have performed an integrated genomic and transcriptomic analysis of 147 Barrett’s 
oesophagus (BE) frozen samples across the grades. The aim was to gain an in depth 
understanding of the biology driving the progression of this disease so that this 
understanding could facilitate the future development of biomarkers for disease diagnosis 
and ultimately the earlier detection of oesophageal adenocarcinoma (OAC). A whole 
genome and transcriptome analysis of all the grades of BE has not previously been 
performed. Furthermore, whole genome sequencing (WGS) permits the analysis of structural 
variants which have never been considered at the pre-invasive stage. In addition, we 
compared the pre-cancer samples to BE sampled from adjacent to cancer in order to see 
whether BE adjacent to cancer is representative of pre-cancer BE or if the tumour 
development can have a local effect on the surrounding BE. We then went on to perform 
multilevel sequencing of 6 dysplastic BE cases to investigate the heterogeneity within 
segments. We used clonal and subclonal mutations and copy number alterations to 
understand degree of heterogeneity and the clonal evolution of BE. Finally, we considered 
how these findings could be applied clinically. 
The strength of this cohort is the meticulous curation. The triple, independent consultant 
pathologist reviews gave us the highest possible certainty of the pathology of the biopsies 
that we sequenced. Patients had long-term follow-up and clear records of any treatment 
intervention. We were able to collate detailed, complete clinical information on each case. 
Good clinical annotation is rare in genomic studies. This allowed the integration of this 
information into progression models. 
Creating such a well-defined cohort did present a number of challenges. We aimed to 
carefully select the frozen biopsies with high cellularity of the grades of interest. In cancer 
WGS studies, a pathological cellularity of 70% is commonly used. This percentage was not 
achievable for the BE because often the frozen research biopsy had not captured the 
dysplasia that the patient was known to have, resulting in the exclusion of most biopsies. We 
used a 30% cellularity cut-off and, importantly, have demonstrated that genomic alterations 
in BE can be confidently called at a depth of 50X WGS. We appreciate the disadvantage of 
only being able to cut and stain a single H&E from each frozen biopsy for diagnosis, due to 
the small size of the biopsies and the need for 2ug of DNA for WGS. It is possible that other 
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pathological grades were captured in the adjacent 2mm of tissue. However, for the main 
analysis, cases were analysed using the highest overall known grade of the patient, from 
FFPE, in order to negate the recognised difficulty in grading frozen tissue. We were unable 
to use microdissection in this study, again because of 2ug requirement for sequencing. Whilst 
this meant a lower cellularity, we avoided the possible introduction of artefact from DNA 
amplification. One point of which we must be aware is the possibility that we missed some 
real single nucleotide variants (SNVs) at low allele frequencies because of the relatively low 
depth of sequencing, the cellularity of the biopsies and the heterogeneity of BE with few 
clonal mutations. Early comparisons of Strelka and Mutect did show that Mutect called a 
slightly higher proportion of SNVs at very low allele frequencies (AF) (<0.1). But this must 
be weighed against the extra false positives that would have been called at these low AFs. 
We preferred to work with SNV calls that we could be confident of. An alternative would 
be to sequence to a higher depth of 100X but this would be very costly. For future work, a 
move towards using a new tissue preservation method, the PAXgene Tissue System 
(PreAnalytiX, Switzerland), could be used. This offers a similar quality of nucleic acid 
preservation as snap-freezing for whole genome and transcriptome sequencing, but 
maintains the tissue architecture for pathology review, as with FFPE tissue. 
A high degree of heterogeneity between cases has previously been demonstrated in OAC 
(Frankell et al., 2019) and in small numbers of BE cases (Ross-Innes et al., 2015a). We 
observed in this large cohort that the heterogeneity of BE extended across the different 
genomic features but with a few key alterations occurring more frequently: particularly copy 
number alterations (CNAs) and mutations in driver genes. There were wide ranges in the 
numbers of SNVs, CNAs and structural variants (SVs) between samples, yet each feature 
appeared to be more of a gradual continuum when samples were ordered. We noticed that a 
specific genomic feature could dominate one sample, e.g. a dysplastic sample with a very 
high number of SVs but a low total mutation burden. In other cases, moderate numbers of 
each feature might be present. Driver mutations were then layered on top. Although de novo 
analyses did not discover any new drivers, this was not surprising given the size of the cohort. 
Using the known drivers in OAC, we were able to look back through the grades to see how 
early the alterations in these genes occurred. We noted a number of driver gene events to be 
specific to the dysplastic stage: TP53 mutation, GATA6 amplification, ERBB2 amplification 
and APC mutation. All seen in >10% of dysplastic cases. ERBB2 and GATA6 demonstrated 
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a mutual exclusivity. ARID1A mutation, whilst seen in some of the non-dysplastic, non-
progressor (ND-NP) cases, was mutually exclusive with TP53 mutation. 
Mutational signatures, in contrast, were less heterogeneous. They were preserved across the 
grades: seen from the early ND stage, both in non-progressors and pre-progressors. This 
suggests that they are set early with the formation of BE and the initial mutagenic 
environment to which the oesophagus is exposed. SV signatures, which have only very 
recently been described, were also preserved across the grades. There was a strong presence 
of signature 5 (dominated by translocations) throughout. 
The possibility to analyse structural variants is one of the strengths of this analysis. So far 
only a basic analysis has been performed. The next step will be to look in more detail at the 
types of SV dominating each sample, rather than the signatures, and the genes affected by 
them. We would hope that further alterations in drivers might be identified. Furthermore, a 
specific look for the presence of mobile elements may help to define the numbers of 
translocations, as these can be confused by the SV caller Manta. 
The transcriptomic analysis identified 475 differentially-expressed genes between ND and 
dysplastic cases. The genes downregulated from ND to dysplastic were also highly expressed 
in duodenum. Pathway analysis revealed the genes to have roles in intestinal development, 
fatty acid synthesis and lipid metabolism. A number of the genes were controlled upstream 
by HNF4A, a transcription factor important in the development of the intestines. These 
results support the theory that the intestinal metaplasia phenotype of the glandular epithelium 
is lost with progression. This has not previously been described on an expression level, 
despite being a phenotypic feature that has long been noted pathologically (Naini et al., 2016; 
Odze, 2006). 
Pathway analyses of the genes upregulated in dysplasia highlighted the importance of the 
upregulation ERK/MAPK signalling pathway in progression. This pathway has previously 
been shown to be upregulated in BE cell lines with acid exposure (Jaiswal et al., 2006; 
Morgan et al., 2004; Souza et al., 2002) but this has not formerly been noted in large studies 
on human tissue. 
Clinically, there is great interest in whether it is possible to identify patients with long-term 
indolent disease from those who are going to go on to progress, in order to guide the need 
for surveillance. In our pre-progressor (PP) cohort of ND samples, we did not see any 
differences in the genomic landscape compared to NP. Specifically, we did not see any TP53 
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mutations in this group, which has been claimed in other studies e.g. (Stachler et al., 2018). 
We appreciate that this was a small group in our cohort because it was very difficult to find 
frozen samples for cases who had long follow-up and progressed. 
Previous WGS sequencing of BE has been performed on BE sampled from adjacent to 
cancer. But it has not been known if this tissue is representative of pre-cancer BE. We found 
that there were no significant differences in mutation burden or CNAs between the pre-
cancer and adjacent to cancer BE, when ND and dysplastic were compared like for like. 
However, for several features, the ND samples appeared more similar to the dysplastic pre-
cancer. There was a wider range of SV counts in the ND BE adjacent to cancer and two 
samples had evidence of chromothripsis. This was not seen in any of the ND pre-cancer 
cases. The spectrum of driver gene alterations in the ND BE adjacent to cancer were also 
more similar to the dysplastic samples, with alterations in GATA6, TP53, SMAD4 and KRAS, 
albeit at low frequencies. However, this raises the issue that investigators need to be careful 
about extrapolating findings to the progression of BE when analysing samples taken at the 
cancer timepoint. It also supports preceding evidence of the local effect caused by the 
adjacent tumour. 
Given the intralesional heterogeneity that has been observed in BE we wanted to look at 
some cases in more detail. We performed multilevel sequencing at 50X on 6 dysplastic cases. 
Analysis of the numbers of genomic alterations, signatures and driver gene alterations 
revealed differing degrees of heterogeneity between biopsies from a single case. Firstly, we 
found that there were some cases where all the biopsies from one case had similar numbers 
of SNVs, CNVs and SVs irrespective of the grade of each biopsy. For example, an IM biopsy 
in case 4 had a similar number of SNVs and SVs to its adjacent HGD sample 1cm distal to 
it. However, in other cases there was more variation between the biopsies e.g. with one 
biopsy with a much higher proportion of rearrangement than adjacent biopsies. In the 
analysis of signatures and drivers we saw further heterogeneity that did not always correlate 
with that seen in the numbers of SNVs, SVs or % of genome altered by CN. The clonality 
analysis, which brought the genomic features together to understand the relationships of 
clones to each other within the samples, further demonstrated the complexity of BE 
segments. For some cases we could construct phylogenetic trees with clear clonal ancestral 
clusters from which subclones developed. Yet, in others no clonal clusters were identified, 
with evidence of parallel evolution. We appreciate that these are 6 anecdotal cases and that 
more are required to make any defining statements about these phenomena. 
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It has been suggested that the diversity of a BE segment may be able to predict progression 
e.g. (Maley et al., 2006). We would like to go on to look at applying these measures of 
diversity to these samples. We have also defined a cohort of multilevel ND cases for a 
comparison in this clonality analysis which we will be sending for sequencing. Moving 
forward, it would be very interesting to be able to expand the multilevel cohort. Whole 
exome sequencing of small amounts FFPE cancer tissue has been optimised in our lab. If 
this could successfully be applied to the BE then the cohort could be expanded more cost-
effectively. Using FFPE tissue would allow a much higher confidence of the grade that is 
being sequenced.  
Overall, it seems that rather than a stepwise process with advancing pathological grades, 
molecularly there is more of a continuum. The current dysplasia status is categorical, in order 
to inform clinical management, but perhaps it is too simplistic. The phenotypic appearance 
is the end-point result of many molecular processes and the genomics suggest that there are 
many possible paths to progression. We hypothesise that molecular features accumulate over 
time until the combination of them is enough to tip the balance to progression. This is very 
important to understand when considering biomarkers for development: there is not one key 
defining genomic feature. A supervised learning algorithm identified SV count to be the 
variable which could best split the data into ND and dysplastic groups. It is interesting that 
SVs were better than CNAs, however technological advances are needed if SVs are to ever 
feature as biomarkers. It may be that further analysis will uncover a small number of 
recurrently rearranged regions which are enough to identify dysplasia. In this situation back-
to-back baits could be designed to focus on sequencing the region. An alternative will be to 
work on a system to assign scores to cases for different genomic features based on their 
position within the continuum for each feature, e.g. SV count. The summation of these 
scores, and the definition of a threshold, could both identify cases with moderate levels of a 
number of features and cases with one overriding, dominant feature. Both which may be at 
a high risk of progression. 
It is true that dysplasia is a reasonable biomarker when diagnosed by an expert GI pathologist 
but, clinically, GI pathologists are not available in every hospital. Potential alternatives to a 
molecular biomarker could be to centralise surveillance/pathology reviews or to work 
towards a machine-learning digital recognition of the grades. Machine-learning can now be 
used distinguish tumour from normal across tissue types on whole slide images (Campanella 
et al., 2019) and recently, correlation has been shown with genomic and transcriptomic 
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features (Fu et al., 2019, unpublished). However, so far work has mainly focussed on OAC 
and work on the pre-malignant stages is only just beginning to advance (Critchley-Thorne et 
al., 2017; El Hallani et al., 2015; Tomita et al., 2019). 
Ultimately, we would like to move away from using phenotypic markers in the pathology 
for diagnosis and move to more quantitative molecular markers, with or without the addition 
of clinical features, to risk stratify patients. In our analysis, we have had to start by using 
dysplasia as a comparison and we consider LGD as progressed. But we know that not all 
patients with LGD would have progressed to cancer (11.6%/year) (Phoa et al., 2014). Now 
that we no longer get long-term follow-up on these LGD patients, because they are all 
treated, we cannot identify those that would have regressed/never progressed further. To 
move away from dysplasia entirely we ideally need to identify potential biomarkers and take 
the study back to FFPE material, where we can go further back in time with longer follow-
up of LGD. 
There are a number of future directions in which this project could be taken and endless 
potential analyses to continue on the cohort. Firstly, there are specific analyses that I would 
like to go on to perform but have been unable to date due to time limitations. Predominantly 
of the structural variants and how they compare in the multilevel cases. There are also more 
comparisons to do with the expression data in comparing different subgroups e.g. the non-
progressors and pre-progressors, and also comparing NDBE to duodenum to see whether 
there are altered genes or pathways that distinguish it and could help to explain its potential 
for progression to cancer. Our lab has performed transcriptome sequencing on large numbers 
of tumours, and I would like to add a subset of these to the analysis to consider the changes 
in expression from the non-invasive IMC to the invasive cancer. A number of other future 
directions have also been mentioned in the discussions of the results chapters but, finally, 
the addition of methylation data would hugely strengthen this cohort and we are working 
towards this. This could then be integrated with the RNA using Multi-Omics Factor Analysis 
software (Argelaguet et al., 2018). For example, we may see changes in the methylation of 
genes in the ERK/MAPK to explain this upregulation. 
This analysis was on a highly curated cohort and further work must look to see if specific 
alterations can be seen on any biopsies, irrespective of grade or cellularity. Again, the easiest 
way to do this would be to move to FFPE samples because of the wealth of banked diagnostic 
material accessible. It would also then be very interesting to track these genomic alterations 
back through time and ascertain when they first appeared. 
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Finally, the overarching aim of this project was to identify new biomarkers that could be 
applied to diagnose dysplasia and improve early detection of these lesions. The differential 
expression analysis has identified a number of candidates to take forward for testing, initially 
with IHC and then in panels, possibly combined with markers from other modalities. 
Overall, we have shown that BE is highly heterogeneous across the molecular features of 
mutational patterns, copy-number aberrations (CNA) and structural variants (SVs). 
However, they reveal a gradual molecular continuum, rather than a stepwise progression 
through the pathological grades. This continuum is punctuated by certain key genomic 
alterations and we hypothesize that it is the accumulation of events that tips the balance to 
progression. 
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Supplementary Table 1 Significantly up and down-regulated genes in dysplastic versus non-dysplastic 
BE 
Only gene with at least a 3-fold change (log2 fold change >1.58 or <-1.58) and adjusted p values < 0.05 are 
included. 
 
Gene ID 
Base Mean 
Counts 
Log2 Fold 
Change p value p adj 
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